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6ABSTRACT
The outcome after renal transplantation (TX) in children has improved, but low recipient
age is still a risk factor for graft failure, impaired growth, and an inferior
neurodevelopmental outcome. Detailed reports on outcome in small children and infants in
the literature are scarce.
In the present study, we report the results of a prospective investigation into long-
term graft survival (GS), renal glomerular and tubular function, renal allograft
histopathology, growth, and neurodevelopmental outcome in small children and infants.
At our center, 59 children under the age of 5 years (mean age 2.3 ± 1.0) when they
received their first renal graft had received 65 grafts between the years 1987 and 1999. The
most common cause of TX was congenital nephrosis of the Finnish type in 48 patients
(81%). Twenty-four patients (37%) were recipients of a living related donor (LRD), and 41
(63%) were cadaver kidney (CAD) recipients. Every patient received triple
immunosuppression (cyclosporine, azathioprine, and methylprednisolone).
The glomerular filtration rate (GFR), renal plasma flow (RPF), concentrating
capacity, sodium-, urate-, and potassium handling were studied for up to 7 years after TX.
Renal allograft biopsies were analyzed according to the Banff classification (BC) and
scored semiquantitatively. The “chronic allograft damage index” (CADI) was calculated. A
neurological examination, magnetic resonance imaging of the brain (MRI), an
electroencephalogram (EEG), audiometry, neuropsychological tests (NEPSY), and tests of
cognitive performance (WISC-R) were performed in 33 school-aged children. The results
were related to school performance and retrospective risk factors prior to TX.
Patient survival of all patients, 7 years after TX was 98%. GS for the first graft
recipients 7 years after TX was 88% for LRD recipients and 80% for CAD recipients (p =
0.5). Graft survival for first transplantations 7 years after TX for children transplanted when
<2 years of age was 85%, and for children transplanted between the ages of 2 and 5 years
81% (p = 0.8).
In recipients <2 years of age, the absolute GFR was 26.3 ± 11.1 mL/min at TX and
27.7 ± 10.3 at 7 years. Recipients >2 years of age improved their absolute GFR
significantly from 29.9 ± 6.7 at TX to 42.6 ± 9.9 at 7 years. However, in recipients <2 and
>2 years of age, the body size-correlated GFR declined from 77.0 ± 27.2 mL/min/1.73m2
and 75.7 ± 18.9 at TX to 46.4 ± 18.2 and 64.0 ± 20.5 at 7 years.
Hyperuricemia occurred in 43-67% of the patients, abnormal handling of potassium
was seen in 17-33% at different time points, and most patients had a subnormal
concentrating capacity during follow-up.
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Most of the biopsies (52-69%) were considered normal according to the BC and the
proportion with chronic allograft nephropathy did not increase with time. The median
CADI score was 2.5 (scale 0-36) at 1.5 years and 3.5 at 7 years. A correlation was shown
between the number of early acute rejection episodes and CADI at 5 years (ρ = 0.67, p =
0.001).
Catch-up growth was seen in 81% of 30 children without growth hormone (GH)
treatment. Children <2 years of age at TX without GH had a mean height standard
deviation score (hSDS) of -1.1 ± 0.8 at TX that remained unchanged at -1.1 ± 0.5 at 7
years; children between 2-5 years at TX improved their hSDS from -1.9 ± 0.9 to -0.4 ± 0.8
(p < 0.0001). The hSDS at TX was inversely correlated with the ∆hSDS from TX to 7 years
(r = -0.80, p = 0.0002). The GFR at 5 years correlated with the subsequent growth rate from
5-7 years after TX (r = 0.58, p = 0.01). Catch-up growth was seen in all 11 children
receiving GH. Their mean hSDS improved from -2.5 ± 0.9 to -1.1 ± 0.9 at 7 years (p <
0.0001).
Twenty-six (79%) children attended normal school and 76% had normal motor
performance. Six of the seven children attending a special school had brain infarcts on
MRI. The children attending the special school had had more hypertensive crises (p =
0.002) and seizures (p = 0.03), mainly during dialysis. Border-zone lesions were seen on
MRI in 18/33 of patients, but were also seen in children with normal cognitive and school
performance. Children with border-zone lesions had histories of several hemodynamic
crises. The EEG was abnormal in 11 (35%) and 5 (15%) had had anticonvulsive treatment
after TX. Sensorineural hearing loss was documented in 6 patients. The mean IQ was 87
and 6-24% showed impairment in neuropsychological tests.
With triple immunosuppression, excellent long-term patient and graft survival, with
good graft function and a low prevalence of chronic allograft nephropathy, can be obtained
even in small children receiving cadaver kidneys. Catch-up growth was seen in the majority
of children and the overall neurodevelopmental outcome in these previously lethal diseases
is reassuring. Recipients <2 years of age receiving an adult kidney seem to lack the capacity
to improve graft function in response to growth, in contrast to older recipients.
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ANOVA analysis of variance
AR acute rejection(s)
ASK adult-size kidney(s)
ATN acute tubular necrosis
Aza azathioprine
BA bone age
BC Banff classification
CAD cadaver donor(s)
CADI/∆CADI chronic allograft damage index/change in CADI
ClEDTA clearance of EDTA
ClLi clearance of lithium
ClNa clearance of sodium
ClPAH clearance of para-aminohippuric acid
Clurate clearance of urate
CR chronic rejection
CrAUC area under the curve for creatinine
CRF chronic renal failure
CS corticosteroids
CsA cyclosporine A
CT computed tomography
EDTA European Dialysis and Transplantation Association
EEG electroencephalogram
FeNa fractional excretion of sodium
FNAB fine needle aspiration biopsy(ies)
FPR fractional proximal tubular resorption
FSGS focal segmental glomerulosclerosis
GFR glomerular filtration rate(s)
GH growth hormone
GS graft survival
hBA/∆hBA height for bone age/change in hBA
HLA human leucocyte antigen
hSDS/∆hSDS height standard deviation score/change in hSDS
IGF insulin-like growth factor(s)
IGFBP insulin-like growth factor binding protein(s)
Abbreviations
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IQ intelligence quotient(s)
LRD living related donor(s)
MP methylprednisolone
MRI magnetic resonance imaging
NAPRTCS North American Renal Transplant Cooperative Study
NPHS1 congenital nephrotic syndrome type 1, formerly congenital
nephrotic syndrome of the Finnish type
NPHS1 the nephrin gene
PLSD protected least significance difference
PSG percentage of sclerotic glomeruli
RPF renal plasma flow
S-Al serum aluminum
SNHL sensorineural hearing loss
TTKG transtubular concentration gradient
TX renal transplantation(s)
UNOS United Network of Organ Sharing
W/H weight for height
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INTRODUCTION
Renal transplantation (TX) is today both the standard and the optimal treatment for end-
stage renal disease in children.1 More than 27,000 kidney transplantations were performed
worldwide in the year 2000.2 Since pediatric patients comprise approximately 5% of all
kidney transplant recipients, more than one thousand renal transplantations are performed
each year worldwide in the pediatric age group.1 The improvement in patient and graft
survival (GS) in recent decades is attributable to improvements in surgical techniques, peri-
and postoperative care, immunosuppressive medication, and diagnosis and treatment of
rejection and infections. Overall patient survival in children is comparable to, or even
better, than in adults.1 However, the youngest children have had inferior survival rates
compared with older children, and young age is still a major risk factor for GS in pediatric
TX,3 particularly in combination with the use of cadaver donors (CAD).
TX in children presents unique features. Treatment should ensure normal growth
and development for the child. Despite the overall good or even excellent patient survival
rates, reports on growth and development after TX have not always been impressive. GS
and the serum creatinine level are only crude measures of long-term graft function. Good
long-term graft function is a prerequisite for the normal development of a child. In addition,
young children are exposed to potent immunosuppressive medication for years, with a
possibly negative impact on renal function, and growth, and an increasing risk of
malignancy. The long-term outcome after TX in small children has not yet been extensively
studied. In single center reports, the numbers of patients are mostly small and, particularly
in multi-center reports, may encompass patients on several immunosuppressive protocols.
The present study was undertaken to evaluate the outcome in all those children who
received a kidney graft when under the age of five years at our center. The children were all
treated uniformly and were assessed prospectively for graft function, graft histopathology,
and growth for up to 7 years after TX. Neurodevelopmental outcome was investigated in all
children who had reached school age (7 years) at the time of the study.
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REVIEW OF THE LITERATURE
RENAL TRANSPLANTATION IN CHILDREN
The indications for TX in children are different from those in adults, in whom the majority
of organ failures are due to acquired diseases. Most pediatric patients have congenital
malformations or a hereditary disease.3 The Finnish disease heritage includes congenital
nephrotic syndrome of the Finnish type (NPHS1, previously CNF), which is the most
common disease leading to TX in our patients. It is caused by two main mutations (Fin-
major and Fin-minor) in a gene (NPHS1)4 coding for a protein named nephrin, which is a
major component of the glomerular filtration barrier.5  Both mutations in NPHS1 lead to
massive proteinuria with secondary complications such as hypoproteinemia, malnutrition,
and lack of important proteins causing coagulation, endocrinological problems, and
infections. In order to minimize these complications, children with NPHS1 are bilaterally
nephrectomized and dialyzed from an early age after receiving albumin infusions, enhanced
nutrition, and pharmacological treatment from birth.6 Children with NPHS1 differ from
other children with end-stage renal failure, since they are not uremic prior to nephrectomy.
Because of the high incidence of NPHS1, the age distribution of children
undergoing TX in Finland differs from that reported in all other international registry
reports. Thus, in Finland, 50% of all transplanted children are under the age of five years
when they receive their first kidney graft,7 compared to 21% in North America.3
Preemptive TX (i.e. TX without preceding dialysis) is an increasing modality in
children, but most of the children are still on dialysis, either peritoneal dialysis (2/3 of the
patients) or hemodialysis, before TX.8 However, severely proteinuric children need to be
nephrectomized and put on dialysis prior to TX in order to correct their coagulation and
their nutritional deficiencies, and to improve their general status.6 Continuous cycling
peritoneal dialysis is the modality used almost exclusively in Finnish patients.9
Approximately half of all kidney transplants performed in children in North
America are from a living related donor (LRD), and this figure has increased from 43% in
1987 to 53% in 1996.3 LRD TX has been advocated particularly for small children. In
Europe, the use of CAD kidneys has been more extensive, but considerable differences in
allocation have been noted between different countries.10 Today, children almost
exclusively receive an adult kidney. The use of pediatric donors in CAD TX is today less
common. The survival rates of pediatric recipients receiving pediatric kidneys have been so
discouraging that the allocation policy has changed.11
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Histocompatibility matching between the donor and the recipient has been utilized, using
the human leukocyte  antigen (HLA) system.12 The HLA antigens usually tested are the
HLA-A, -B, and –DR antigens. The beneficial effect of minimizing histocompatibility
mismatches has been shown in both adults and children.3,12 GS has been even better in zero-
mismatched CAD grafts than in haploidentical LRD grafts.13
A limited number of pre-transplant blood transfusions has been shown to decrease
the rate of acute rejections (AR), but >5 transfusions has resulted in inferior GS, for both
LRD and CAD kidneys.14 The beneficial effect of pre-transplant transfusions seems to have
diminished since the introduction of more potent immunosuppression.15
TX in children is performed using techniques similar to those used in adults.
Extraperitoneal placement is also preferred in children. Placing of the kidney
intraperitoneally has been advocated for children weighing <15 kg.1 However, in our
experience an adult kidney can safely be  placed extraperitoneally in an infant weighing
over 9 kg.16 Graft thrombosis is one of the major risk factors for early graft loss in children,
particularly in recipients <2 years of age.17 In a report by Kim et al.,18 graft failure attributed
to thrombosis occurred more frequently in patients with congenital nephrotic syndrome
than in patients with other primary diseases (8.3% vs. 2.9%, p = 0.002).18
IMMUNOSUPPRESSION
Organ transplantation would not be possible without potent immunosuppressive drugs.
Triple immunosuppression consisting of cyclosporine A (CsA), corticosteroids (CS) and
azathioprine (Aza), has remained the most popular maintenance therapy worldwide after
pediatric TX. Today, the use of Aza is decreasing, but CsA is still included in the
immunosuppressive protocol in 80% of children. CS have been the mainstay in pediatric
TX, and are used as adjunct therapy in over 90% of protocols.19
Cyclosporine
The drug used most widely in maintenance immunosuppression, CsA, is unfortunately
nephrotoxic and may injure the allograft and contribute to chronic allograft dysfunction. It
is impossible to discuss long-term function or histopathology after TX without reviewing
the effects of CsA. Briefly, CsA inhibits a phosphatase called calcineurin, thus preventing
transcription of the interleukin-2 gene, which in turn prevents proliferation and generation
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of cytotoxic T-cell precursors.1 CsA causes changes on the allograft that can be divided into
functional (usually reversible) and structural (often irreversible) changes.
CsA induces arteriolar vasoconstriction and hypoperfusion of the kidney that lead to
a decrease in the glomerular filtration rate (GFR). These functional changes are also seen in
patients with autoimmune diseases and in kidneys of healthy volunteers treated with
CsA.20,21 The effect of CsA is dose-dependent and is mostly reversible22 and, thus, more
frequent immediately after TX in connection with high CsA doses. Hyperkalemia, mild
metabolic acidosis, hypomagnesemia, hyperuricemia, and decreased urinary concentrating
capacity, all possible signs of tubular dysfunction, have been reported as complications of
CsA therapy.23-28
Structural changes such as microangiopathy, involving small vessels and glomeruli,
and tubulointerstitial changes might be expected to have a more profound effect on long-
term allograft function and histopathology. However, no morphological lesions seen in
vessels, glomeruli, or the tubulointerstitial space are solely attributable to CsA toxicity.29
CsA has a narrow therapeutic window between clinical efficacy and toxicity. CsA
bioavailability is mainly influenced by drug absorption, which shows great variability
among patients. The bioavailability has improved with the use of the microemulsion form
of CsA, but dosing of CsA should be accompanied by pharmacokinetic measurements. It
has traditionally been based on blood trough level measurements of the drug. However,
trough level determinations poorly predict exposure to the drug compared to area under the
curve determinations based on several 24-hour measurements. The latter method, however,
is impractical for clinical use and several sparse-sampling methods have been developed
which predict drug exposure more accurately (e.g. a single sample 2 hours after the CsA
dose).30
Other immunosuppressants
The other main immunosuppressant in use, tacrolimus, is also a calcineurin inhibitor.
Shapiro et al. have reported a GS of 89% in children, including both LRD and CAD
recipients, 5 years after TX.31 Nephrotoxicity is a problem as with CsA, but the main
concern with tacrolimus is the higher incidence of lymphoproliferative diseases,
particularly in children.31
Aza, CS and mycophenolate mofetil are drugs used for adjunct therapy in
combination with CsA and tacrolimus, which are considered to be the main
immunosuppressants. Aza and mycophenolate mophetil are both inhibitors of purine
synthesis. CS have numerous immunosuppressive and anti-inflammatory effects,
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macrophages being particularly sensitive. These steroids inhibit arachidonic acid release
and hence eicosanoid production. They also reduce secretion of neutral proteases and
interleukin-1. They interfere with antigen presentation, inhibit the primary antibody
response, and reduce the numbers of circulating T cells.32 Because of the many adverse
effects of CS therapy (e.g. increased susceptibility to infection, subcapsular lenticular
opacities, aseptic necrosis of bones, hypertension, hyperlipidemia, diabetes, Cushingoid
appearance, growth retardation), there has been substantial interest in either reducing the
dose or withdrawing CS completely (see also later growth section). However, withdrawal
of CS increases the incidence of AR.33,34 Although some studies have been successful in
withdrawing CS, there is a lack of any immuno-biologic marker to indicate from which
patients steroids can be safely withdrawn.35 A new synthetic steroid, deflazacort, has been
studied and seems to be more promising with regard to the side effects of steroids.36
Polyclonal and monoclonal antibodies against T-lymphocytes are also used as
induction therapy at the time of grafting. Recently, monoclonal antibodies against more
specific targets have been developed. Basiliximab is a monoclonal antibody against the
interleukin-2 receptor, which is used to prevent early AR. The more specific targeting also
results in fewer side effects. In a recent multicenter report, basiliximab significantly
reduced the incidence of AR in patients on triple therapy.37
PATIENT AND GRAFT SURVIVAL
Patient survival
In the latest registry report of the North American Pediatric Transplant Cooperative Study
(NAPRTCS), overall patient survival in all children, 5 years after TX, was 93.5%.38 There
was no significant difference in patient survival according to donor source, except in infants
(0-1 years), where patient survival was 79.1% and 90.1% in CAD and LRD recipients,
respectively. In the European registry (European dialysis and transplant association-
EDTA), the 5-year survival for patients <5 years of age was 84% in TX performed after
1985.39 Patient survival has clearly improved with time; overall survival for CAD recipients
improved from 74% for children grafted before 1980 to 91% for those grafted after 1985.39
Superior long-term results have been reported from single centers, with 100% 5-year
patient survival for infants receiving LRD kidneys40 and up to 90% after 8 years in series
including infants with both LRD and CAD kidneys.41
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Infections are the most frequent causes of death after TX in children, accounting for 34% of
patient loss.3 Cardiopulmonary causes account for 17% of patient deaths in the NAPRTCS
registry report.3 Probably the most severe side effect of any potent immunosuppression is
an increased risk of malignancy.42,43 In a multi-center study by Opelz et al.,43 the risk of
non-Hodgkin lymphoma was related to the aggressiveness of the immunosuppressive
regimen in kidney- and heart-transplanted patients.43 In the 1997 NAPRTCS registry report,
the incidence of malignancy during the course of the registry was 1.6% and accounted for
almost 10% of all patient deaths. The most common malignancies were lymphoproliferative
diseases.3 The high incidence of lymphoproliferative diseases related to the newer potent
immunosuppressive drugs, such as tacrolimus, has been of particular concern.31
Graft survival
In the 1998 NAPRTCS report, overall GS 5 years after TX was 80% for children receiving
LRD kidneys and 65% for recipients of CAD kidneys.38 According to age, GS was 80% for
LRD recipients 0-1 years and 2-5 years of age but only 52% and 69% for CAD recipients 0-
1 and 2-5 years of age, respectively.38 The number of patients is limited, but the inferior GS
in CAD recipients in contrast to LRD recipients is also obvious in the majority of single
center reports. Humar et al. reported a GS of 86% in infants with LRD grafts and CsA, not
significantly different from the results in older children.40 Kari et al. reported a 100% GS in
LRD recipients less than 5 years of age compared to 55% for CAD recipients at 5 years.44
The report by Cochat et al. is an exception, with a GS of 89% at 5 years in 9 CAD
recipients (however, only 3 patients were followed for 5 years).45 However, the
improvement in short-term GS has been more remarkable with CAD than with LRD
kidneys. In a special report by NAPRTCS focusing on CAD GS, one-year GS had
improved more than LRD GS from 1988 to 1996 (by 16% compared to 5%).46 Millan et al.
have reported a 2-year GS of 100% in infants including both CAD and LRD recipients
(CsA or tacrolimus as main immunosuppression).41 The long-term (at least 5 year) GS rates
in infants and small children during the last 10 years are summarized in Table 1.10,38,40,44,47-55
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Table 1. Graft survival after renal transplantation in infants and small children with cyclosporine as
main immunosuppression.a
Author/Year
(Registry)
Recipient age
(years)
All (LRD/CAD)b 5-year graft survival (%)
All LRD CAD
Gjertson 200150
(UNOS)
0-3 245 82 NA NA
Seikaly 200138 0-1 326 (237/89) NA 80 52
(NAPRTCS) 2-5 910 (501/409) NA 80 69
Dall´Amico 200149 <6 41 (2/39) 70 NA NA
Ishitani 2000c 51 <2 161 (161/0) 71 71 NA
(UNOS) 2-5 331 (331/0) 78 78 NA
Cransberg 200048 <4 13 (NA) 38 NA NA
Sarwal 2000d 53 0-2 29 (NA) 84 NA NA
2-5 16 (NA) 84 NA NA
Kari 199944 <5 59 (10/49) 57 100 55
Humar 199840 <1 26 (25/1) NA 86 NA
1-4 92 (59/33) NA 82 NA
Vester 199855 <6 52 (19/33) 78 90 70
Tyden 199754 <2 21 (15/6) NA 87 44
Johnson 199652 <5 26 (0/26) 59 NA 59
Broyer 199310
(EDTA-ERA)
<5 266 (0/266) NA NA 52
Briscoe 199247 <2 22 (14/8) NA 86 38
aAbbreviations: CAD, cadaver donor; LRD, living related donor; NA, not assessed
bNumber of transplantations
cGraft survival at 7 years
dGraft survival at 8 years, including patients with tacrolimus and cyclosporine
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Causes of and risk factors for graft survival
Chronic rejection (CR) is the leading cause of graft failure in both registry- and single
center reports.38,56 In the 1998 NAPRTCS report, CR caused index graft failure in 31.2%,
AR in 16.4%, and vascular thrombosis in 12.1%, and death with a functioning graft in
10.1% of children.38 AR episodes are a major determinant for the development of CR.57-59
Ca us e s a n d r i s k f a c t o r s f o r g r a f t f a i l u r e r e p or t e d i n t he l i t e r a t u r e a r e s u m m a r i z e d i n Ta bl e 2 .
Table 2. Causes of and risk factors for graft failurea
Preoperative factors
Center effect
Year of transplantation
Dialysis/pre-emptive transplantation
Retransplantation
Recipient factors
Age
Race
Donor factors
LRD/CAD
Age
Cold ischemia time
Donor disease
Organ preservation
Immunologic
HLA mismatch
Panel reactive antibody
Blood transfusions
Perioperative and short-term postoperative factors
Surgical/technical complications
Delayed graft function/Acute tubular necrosis
Vascular complications
Thrombosis
Renal artery stenosis
Immunologic factors
Acute rejection
Infections
Cytomegalovirus
Immunosuppression
Long-term postoperative factors
Chronic rejection/Chronic allograft dysfunction
Multifactorial etiology
Nephrotoxicity of immunosuppressive drugs/other medical treatment
Hypertension
Hyperlipidemia
Recurrence of original disease/de novo kidney disease
Non-compliance
Death with functioning graft
Infection
Malignancy
Cardiovascular causes
aMany of the factors are interrelated
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Maintenance immunosuppression with calcineurin inhibitors (CsA or tacrolimus) has had a
very central role for short-term GS, but the effect almost vanishes with respect to 5-year
GS, according to the latest UNOS (United Network of Organ sharing in the United States of
America) multivariate registry analysis.50 Treatment with calcineurin inhibitors is an issue
of balance between  efficacy (i.e. preventing alloantigen dependent immune reactions)60 and
on the other hand the unfortunately inherent nephrotoxicity.61 However, few grafts are
explicitly lost because of acute CsA toxicity, which is regarded as a cause in only 0.6% of
graft failures.38
Although the youngest children and infants seem to have the poorest survival rates,
their results stabilize over time , in contrast to adolescents, who show decreasing long-term
GS. In the UNOS registry report on pediatric LRD recipients, adolescents (aged 13-18) had
the best GS in the beginning but survival decreased to only 55% at 7 years.51 This has
mainly been explained by the well-recognized problem of non-compliance in teenagers.62
Causes of graft failure in infants differ in some respects from those in older
children. In the UNOS report covering pediatric LRD recipients, graft thrombosis was
responsible for 23.8% of graft loss in children <2 years of age compared to only 5.9% in
children 6-12 years of age.51 Acute tubular necrosis (ATN) is one of the major risk factors
for graft thrombosis in both LRD and CAD recipients.17 Thus, superior GS rates have been
reported in infants and small children without ATN.53 Surgical technique and experience,
perioperative management, etc, may have a major impact on vascular and immediate post-
operative complications, but these factors are difficult to assess.63
Although the immunologic prerequisites in CAD and LRD grafts are different, a
longer period of cold ischemia is inherent in CAD TX. CAD grafts are especially prone to
delayed graft function, which has a detrimental effect on GS.64 TX performed with living
unrelated donors have had results equal to LRD TX, which supports the importance of the
unfavorable effects of non immunologic factors intrinsic to CAD TX.65
The risk of graft loss is increased by both young and old donor age. Harmon et al.66
calculated a risk of graft loss from a neonate donor as 2.7-fold and the risk from a 50-year
old donor as 1.8-fold that of the ideal donor (i.e. 20-25 years). The relationship between
donor age and GS was not affected by the age of the recipient.66 The results of TX using
pediatric donors has been so devastating that UNOS has changed the allocation policy of
offering pediatric kidneys to pediatric recipients.11 The main complication associated with
young donor age is graft thrombosis.17,52 The effect of older donors is explained by the
physiological deterioration of graft function and declining renal mass known to occur with
age, which in turn affect the supply of viable nephrons offered to the recipient.67,68
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Hypertension after TX is more frequent in pediatric recipients of CAD allografts, and only
AR status has been shown to predict subsequent graft failure more strongly than use of
antihypertensive medications.69 In some studies, hypertension was a consequence of
reduced renal function rather than a direct cause of graft damage.70
Some diseases are more prone to recurrence than others. Focal segmental
glomerulosclerosis (FSGS) is the most common acquired disease in children and has a high
rate of recurrence with graft loss after TX.3 A high rate of re-nephrosis is encountered in
transplanted NPHS1 patients.71 TX in children with FSGS forms an exception to the normal
rule of LRD advantage. Disease recurrence is more frequent in LRD recipients with FSGS
and the GS rates are similar to those obtained with CAD kidneys.72
Death with a functioning graft is mainly caused by infection, cardiovascular disease,
or malignancy. However, it is also influenced by age, original disease, and donor source.73
It has a major impact in assessing GS rates, even though the graft has, by definition,
“survived”.74
Repeat CAD transplants have shown to have an inferior GS compared to primary
transplants.75 Several other factors are reported to influence long-term GS in children, on
the basis of large multicenter registry reports; transplant center, race, year of TX (i.e.
reflects the overall improvement of results during the last few decades), panel reactive
antibody (PRA%), HLA mismatch, pre-emptive TX, absence of T-cell induction therapy,
and pre-transplant blood transfusions (Table 2).3,50,51
LONG-TERM RENAL FUNCTION
Glomerular function and renal plasma flow
Thorough reports in the literature on long-term renal function after TX, particularly in small
children, are scarce. Most studies evaluating renal function after TX have used serum
creatinine or estimates of its clearance. Serum creatinine is too insensitive, particularly in
small children with an adult graft. In chronic renal failure (CRF), the increase in serum
creatinine is not closely related to the decrease in GFR. Creatinine is progressively
hypersecreted by the renal tubules as the nephropathy increases.76 Formulas based on serum
creatinine (e.g. the Schwartz formula)77 tend to overestimate the true GFR, particularly
when the function is impaired.78 In a study by McDiarmid et al.,79 on a pediatric population
receiving CsA, the calculated GFR overestimated the true GFR (measured by indium-111-
DTPA plasma clearance) by 38%.79
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Table 3 shows long-term GFR in studies collected during the last 10 years, all with CsA as
the main immunosuppressant. The corrected GFR range is from 40 to 70 mL/min/1.73m2 4-
6 years after TX.34,44,49,54,55,80-86
Table 3. Long-term graft function after renal transplantation in childrena
Author/year Recipient age Number of
TXb
Years after
TX
GFR
mL/min/1.73m2
Method
mean/median
(range)
All
(LRD/CAD)
All (LRD/CAD)
Dall´Amico 200149 3.2 (1.4-5.9) 41 (2/39) 5 67 Schwartz
formula
Sorof 199984 10.9 85 (31/54) 5 46 (52/40) Schwartz
formula
Kari 199944 2.9 (1.4-5.0) 59 (10/49) 5 40 ClEDTA
Dubourg 199881 10.4 (0.7-17.2) 120 (22/98) 5 70 Clinulin
Vester 199855 3.2 (0.8-5.9) 52 (19/33) 5 56 Schwartz
formula
0-1 227 5 NA (73/67)Warady 199785
(NAPRTCS) 2-5 577 5 NA (62/67)
Schwartz
formula
Berg 199780 7.2 (0.4-20.5) 90 (68/22) 5 40-60c Clinulin
Tyden 199754 1.3 (0.5-2) 21 (15/6) 5 55 Clinulin
Gellert 199682 12 (3-17) 114 (NA) 4 54-60c ClEDTA
Chao 199434 ≤ 15 39 (9/30) 5 46 Schwartz
formula
Williams 199486 13 16 (6/10) 4 58 ClIothalamate
Hoyer 199083 11.3 (1-16) 80 (14/66) 5 42 Schwartz
formula
aSome of the values are extrapolated from figures and may not be exact.
bNumber indicates the original cohort of patients, which after TX usually diminishes with time. NA = not
assessed
cVariation depending on different donor groups.
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Long-term renal plasma flow (RPF) has rarely been measured in children after TX. In 105
children with a mean age of 12 years, 4 years after TX, studied by Gellert et al.,82 RPF
ranged from 254 to 298 mL/min/1.73m2.82 In 53 children with a mean age of 7.8 years,
Berg et al.87 have reported a RPF of approximately 280 mL/min/1.73m2 5 years after TX.87
Hypertension
Hypertension is mostly defined as use of antihypertensive medication, without
measurement of true blood pressure levels. In the registry report of NAPRTCS, the
incidence of antihypertensive medication decreased from 79% 1 month after TX to 58% 5
years after TX.69 In many single center reports, the need for antihypertensive treatment
shows a decline with time, down to 30%88 and 19%44 at 5 years. However, higher figures
have been observed by Hoyer et al.,89 who 4 years after TX in CsA treated children reported
a prevalence of 77%.89 In a study with 24-hour ambulatory blood pressure monitoring
performed in 42 patients with stable renal function, blood pressure readings were elevated
in 50-59% of the children at a mean of 34 months post TX.90
Use of antihypertensive medication has been associated with significantly higher
rates of subsequent graft failure, particularly for recipients of CAD allografts.69 In a study
of adult CAD recipients, systolic, diastolic, and mean arterial blood pressures at 1-year post
TX strongly predicted GS when adjusted for baseline renal function.91 In some studies,
hypertension per se was much more a consequence of reduced renal function than as a
direct cause of graft damage.70 However, the complex nature of post-transplant
hypertension has made it difficult to discern whether its occurrence is the cause or the
consequence of chronic allograft dysfunction. The possibility remains that, in many
patients, the two processes are not mutually exclusive and may coexist.92
The introduction of CsA has been suggested to increase the prevalence of
hypertension in recipients of solid organ transplants.93 CsA increases renal vascular
resistance by causing vasoconstriction which leads to hypertension.94 In a double-blind
study with healthy adult volunteers, CsA raised blood pressure significantly, with a
concomitant rise in renal vascular resistance and a fall in GFR as compared with the
controlgroup.20 However, hypertension has been reported, 5 years after TX, in 71% of
children without CsA treatment.95
Recipients of CAD kidneys have been shown to have more often hypertension than
recipients of LRD kidneys.96 Early ischemia-reperfusion injury (which is more frequent in
CAD TX) has been shown to correlate with later hypertension.97 Many other factors, such
as renal artery stenosis,98 the presence of hypertension before TX, reduced graft function,
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and maintenance therapy with CS,99 influence the prevalence of hypertension after TX. In
addition to the increased risk of graft failure, a major risk factor for cardiovascular disease
is hypertension.100,101
Tubular function and handling of electrolytes
Normally, approximately 1% of the filtered load of sodium is excreted in the urine, and
most is reabsorbed in the proximal tubules (up to 60% in experimental studies).102
Clearance of lithium (ClLi) has been used as a measure of proximal tubular resorption, since
lithium is considered to undergo proximal resorption in the same manner as sodium.103
Newer investigations have questioned this reliability; however, it is still considered a useful
marker of changes in the fractional delivery of sodium and water from the proximal
tubules.104
A number of studies have shown increased proximal tubular resorption (FPR)
during CsA treatment.105-107 Dieperink et al. have shown that when CsA was given to
patients with extrarenal disease and a normal GFR, this increased proximal resorption
persisted for months after withdrawal of CsA.105 In a study by Hansen et al.,108 on renal
transplant recipients with a low dose of CsA and a stable renal function, no specific CsA-
induced renal hemodynamic or tubular dysfunction was evident. In CsA-treated recipients
with slightly reduced renal function (serum creatinine 125-180 µmol/L), FPR was found to
be decreased.108
Hyperkalemia in renal transplant recipients usually reflects the degree of uremia,
but it may occur transiently during normal graft function. Hyperkalemia is more frequent in
renal transplant recipients treated with CsA.23 The proximal tubule reabsorbs approximately
65% of the potassium load, but the potassium balance is mainly influenced by secretion in
the distal nephron.109 Potassium secretion is dependent on the flow rate and the potassium
concentration in the cortical collecting duct.109 The transtubular concentration gradient
(TTKG) has been utilized as a method for evaluating potassium secretion, being more
appropriate than the potassium excretion rate. It is a semi-quantitative reflection of the
potassium concentration in the tubule fluid against that in the peritubular vessels.109,110
Kamel et al.111 assessed the TTKG response during hyperkalemia in adult renal transplant
recipients with CsA and found it to be significantly lower than in control subjects,
suggesting a reduced ability of the distal nephron to secrete potassium.111 The decreased
potassium secretion probably reflects a direct tubulotoxic effect of CsA, since, in animal
studies, there is evidence of a direct inhibitory effect of CsA on both basolateral Na+/K+ –
ATPase and apical K+ secretory channels.112,113 Further evidence for this has been derived
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from the experimental finding that this process involves calcineurin.114 However, the
hyperkalemia induced by CsA is multifactorial, and extrarenal mechanisms may also be
involved.24,26
Hyperuricemia is common after TX and is seen particularly during CsA treatment.28
The major modes of handling urate have been described as filtration, resorption, secretion,
and postsecretory resorption in the tubules. The major part of the urinary urate is considered
to be derived from secretion.115 Diuretics are frequently used after TX and they can both
increase and decrease urate excretion. The latter is usually a result of long-term
administration and is probably explained by contraction of the extracellular volume.115 An
independent tubular effect of CsA has been proposed, particularly increased proximal
tubular resorption of urate.24,27 Impairment of tubular secretion in CsA-treated transplant
recipients has also been proposed in some studies.116,117 Some authors have attributed the
decreased renal urate excretion solely to a decreasing GFR.118 Hansen et al.108 supported this
view in a study in which where the authors compared renal transplants recipients receiving
low dose CsA (<5mg/kg) with recipients on Aza. The clearance of urate (Clurate) was
comparable in the two groups, regardless of immunosuppression, but a significant
correlation between GFR and Clurate was found in both groups.108
In a study of pediatric recipients receiving CsA, 39% had hyperuricemia at 6
months and 23% at 30 months post TX. The authors attributed the decreasing incidence to
the diminishing use of diuretics with time.119 However, the renal function was also worse in
the hyperuricemic group.119
It seems that, after TX, CsA does not influence the calcium-phosphorus
homeostasis.120 However, a significant problem that may occur in up to 50% after TX is the
persistence of secondary hyperparathyroidism, which may lead to both hypercalcemia and
hypophosphatemia.121 Hypophosphatemia may also be related to the use of steroids.24
Hypomagnesemia is often seen soon after TX, but usually resolves with time.122
Renal tubular acidosis in the early days following TX is predominantly a sequela of
acute renal failure, but may be due to CR or CsA induced nephrotoxicity.24
The mean urine osmolality has been lower in CsA-treated than in Aza-treated renal
transplant recipients after 12-hour overnight deprivation of water.123 Laine et al. have
previously shown that, in up to 90% of children urinary concentrating capacity was reduced
3 years after TX.124
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Functional adaptation of an adult kidney to a pediatric recipient
Pediatric recipients of all ages mostly receive adult-sized kidneys (ASK). It has been shown
that an ASK can adapt its function to meet the requirement of a child with a smaller body
size.125 However, this adaptation may not be optimal. Shokeir et al., have demonstrated that,
despite corrections for body surface area, adult kidneys transplanted into pediatric
recipients have a lower GFR than those transplanted into adults.126 The authors speculated
that the difference might be explained by reduced renal perfusion in the pediatric patients.
Salvatierra et al., have shown that infants receiving ASK immediately after TX increased
their aortic blood flow in order to perfuse the ASK. Renal artery blood flow was still
suboptimal compared to the pre-nephrectomized values in the donor. After 4-6 months the
renal artery blood flow continued to decrease, despite continued maintenance of optimum
intravascular volume. The authors speculated that this might either have been the result of a
functional adaptation or that the suboptimal renal perfusion led to some ischemic atrophy in
the graft. A 26% reduction in renal size was additionally noted.127 With more aggressive
optimization of intravascular volume by nasogastric or gastrostomy tube feeding in infants
receiving ASK, the same authors showed an improved GFR at 1 year of 102 ± 10 compared
to 66 ± 3 mL/min/1.73m2 in the controls, prior to the changed treatment protocol.128
A probably more important question is whether a graft can increase its function as
the child grows. Hoyer et al.83 demonstrated that the mean absolute GFR remained stable in
12 CsA-treated children after TX. However, as the mean body surface area increased in the
growing child, the GFR corrected for body surface area inevitably declined with time.83 In a
study by Berg et al.80 including 85 children and adolescents, the mean absolute GFR
remained stable for years in the three age groups studied (<5, 5-12, >12 years), but the
relative GFR (corrected for body surface area) remained stable only in the group >12 years
of age.80 It seems plausible to suppose that the greater increase in body surface area with
time in small children leads to incapacity of the graft to adapt to the growth of the child.80
The impact of donor age on graft function in transplanted children has been studied
by Gellert et al.,82 who divided CAD into a pediatric donor group (median age 7 years) and
an adult group (median age 34). The grafts from  adult donors had a better GFR by 1 month
after TX (75 ± 23 vs. 65 ± 22 mL/min/1.73m2). Although not statistically significant, the
GFR had then declined to 54 ± 20 in the adult donor group, but remained more stable in the
pediatric donor group (60 ± 21) 4 years after TX.82 Dubourg et al.81 noted a similar finding
when they divided donors into two groups (<18 years vs. >18 years). By 3 months after TX,
the adult donor group had a significantly higher GFR than the pediatric donor group (80.6 ±
36.9 vs. 65.1 ± 22.0 mL/min/1.73m2). However, after 4 years the results were reversed: the
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adult donor group had a significantly decreased GFR, 54.5 ± 17.2 whereas the GFR of the
pediatric donor group remained stable at 74.2 ± 27.8 mL/min/1.73m2. The absolute GFR of
the adult donor group had remained stable, while the absolute GFR of the pediatric donor
group had significantly improved with time in response to the increasing demand of the
growing child.81 This finding was also confirmed by Berg et al., who divided the donors
into two groups (<20 vs. >20 years) and found an increased absolute GFR with time only in
the group with younger donors.80 Thus, it seems that grafts from child and adolescent
donors can improve their GFR in response to the demand of the growing recipient.
It is not clear whether the improvement in the absolute GFR is a result of
hyperfiltration or a true hypertrophy/physiological increase of graft function. It has been
shown that children have a functional reserve capacity after renal TX.126,129 It has also been
shown that children maintain their functional reserve capacity years after TX, and
consequently, do not maximally hyperfiltrate.1 3 0  In experimental studies in rats,
compensatory hypertrophy of transplanted kidneys has been shown. In addition, the
morphological changes were also partly reversible when the physiological demand for
increased graft function diminished.131 However, a transplanted kidney is subject to injury
and normal physiological conditions are not necessarily present in the transplant recipient.
Hansen et al have revealed that the sensitivity to certain physiological tests (e.g. a super-
sensitivity to circulating noradrenaline and an inadequate response to negative pressure in
the lower body) is altered in recipients years after TX as compared with controls,
suggesting that the transplanted human kidney remains functionally denervated.132
LONG-TERM RENAL HISTOPATHOLOGY AND CHRONIC ALLOGRAFT
NEPHROPATHY
Scoring of renal histopathology
Analysis of percutaneous renal biopsies is a central tool for establishing an accurate
diagnosis in clinical nephrology.133 Renal biopsies are considered to be a safe diagnostic
tool in pediatric TX.134 Subsequently, the analysis of renal allograft histology has become of
the greatest importance for evaluating the degree and severity of graft rejection and other
changes not considered to be due to rejection.
There are numerous reports in the literature on individual histopathologic changes in
renal allografts and their correlations with renal function and graft outcome. Accordingly,
efforts have been made to establish internationally standardized criteria for the histological
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evaluation of renal allograft biopsies135 and, as of 1995, approximately 70% of US centers
were employing the Banff classification (BC) for biopsy interpretation.136 The BC has six
main diagnostic categories, which are subsequently divided into subcategories (Table 4).
Glomerular, interstitial, tubular and vascular lesions of AR and CR are defined and scored
semiquantitatively from 0 to 3.135,137 The BC (also later revised versions)137 is focused
mainly on changes in the allograft related to AR. The type (severity) of AR according to the
classification has been shown to be associated with graft outcome.138
Table 4. Diagnostic criteria for renal allograft biopsies according to the
Banff classification
1. Normal
2. Hyperacute rejection
3. Borderline changes
4. Acute rejection
Grade I, mild acute rejection
Grade II, moderate acute rejection
Grade III, severe acute rejection
5. Chronic allograft nephropathy
Grade I
Mild chronic transplant nephropathy
Mild interstitial fibrosis and tubular atrophy
Grade II
Moderate chronic transplant nephropathy
Moderate interstitial fibrosis and tubular atrophy
Grade III
Severe chronic transplant nephropathy
Severe interstitial fibrosis and tubular atrophy and tubular loss
6. Other
Other detailed assessments of histology have been developed for detecting more subtle
chronic changes in renal allografts. The “chronic allograft damage index” (CADI) has
previously been shown to correlate with decreasing graft function and to predict subsequent
deterioration of graft function.139,140 This scoring system individually scores several specific
histological findings in the biopsy specimens. The CADI score index is then calculated as
the sum of the scores of those histological changes usually manifested in long-term
allograft biopsies, regardless of their etiology. A high CADI score is consistent with severe
chronic allograft damage. A single score can also easily be statistically interpreted, used for
different correlations such as graft function, serve as a surrogate endpoint for graft failure in
comparing different treatments etc. In the original paper presenting the CADI index, the
scoring system was based on a scale from 0-3, giving a maximum score (i.e. maximum
damage/impairment) of 18.139 The CADI scoring system has later been refined using a scale
from 0-6 (max. 36), which is more appropriate if the findings are mild.124
Other scoring systems resembling the CADI have also been developed, e.g. the
“chronic graft damage” (CGD), which has been shown to predict later graft loss.141
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Chronic allograft nephropathy
CR is the most common cause of long-term allograft loss in both adults and children. In the
1998 annual NAPRTCS report, the most frequent cause of graft failure was CR in 31%.38
The introduction of CsA has not reduced this incidence. CR has been the most common
cause of graft loss in both CsA and non-CsA treated children.56 Interpretation of the long-
term effects of CsA on renal allograft histopathology is one of the most important clinical
issues, since the optimizing of immunosuppression depends on whether or not toxic
changes caused by CsA in the biopsies are found. The differential diagnosis between
rejection and CsA toxicity is difficult, since both may affect vessels, glomeruli, and the
tubulointerstitial space.142 Some of the changes occurring in both entities can be seen only
by electron microscopy.142 However, the renal effects of CsA are indisputable; in some
centers the cumulative incidence of end-stage renal failure in cardiac transplant recipients
has reached 10%.143
CR has been defined as a slow, insidious, progressive deterioration of renal function
not attributable to other causes of kidney dysfunction and confirmed by renal biopsy.136 The
detailed pathophysiology of chronic allograft dysfunction or nephropathy is elusive. Since
both immunologic and non-immunologic factors seem to play a role in the development of
this entity, chronic or late allograft dysfunction or chronic allograft nephropathy would
probably be a more appropriate term to use.137,144 The following interpretation is based
solely on the main findings in light microscopy, which is the diagnostic tool mostly used in
the clinical setting.
The main histopathologic features associated with chronic allograft nephropathy
include; interstitial fibrosis, tubular atrophy, characteristic glomerular changes and vascular
lesions, particularly fibrous thickening of the arterial intima.135,145,146 Although the
histopathologic findings may predict later graft loss, they often exist concomitantly with
already deteriorating graft function.146 On the other hand, histological signs of chronic
allograft nephropathy were present in 50% of biopsies at 2 years, even in patients with
functioning grafts and without a clinical history of AR.139 However, in a report by Legendre
et al., nephropathy was absent in the recipients of HLA-identical kidneys.147 Mihatsch and
colleagues have reviewed 1500 transplant biopsies performed more than 6 months after TX.
About 50% showed some signs of rejection (acute or chronic, often concomitantly); 25%
glomerulonephritis, CsA toxicity, and other specific renal diseases, and 25% unspecific
damage, which the authors preferred to call chronic transplant nephropathy. Mere
interstitial fibrosis in the absence of specific vascular and/or glomerular changes was not
sufficient for the diagnosis of CR.148 Unfortunately, late biopsies years after TX that show
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impaired graft function unfortunately afford little chance to determine the etiology of the
morphologic findings.142
The primary lesion in chronic vascular rejection is endothelial damage, recruiting of
lymphocytes and monocytes, and proliferation of myofibroblasts. Finally, concentric
intimal fibrosis finally occurs, resulting in luminal narrowing.137,142 In long-term studies of
well-functioning allografts, the pathological vascular feature most often seen is intimal
proliferation (fibrosis).139 The presence of active inflammatory cells in the vessels is
classified as acute/active rejection.137 Nodular hyaline deposits in the arteriolar wall can be
seen concomitantly with CsA treatment. After the use of certain stains, hyalinization is the
descriptive term used for acellular material consisting particularly of plasma protein
insudates. When the dose of CsA is reduced or stopped, reversibility and remodeling after
CsA arteriolopathy can be seen. However, arteriolar hyalinization can also be found in
relation to hypertension and diabetes mellitus142 and the result may be a narrowing of the
arteriolar lumen. This may lead to glomerular collapse, glomerular obsolescence, tubular
atrophy, and interstitial fibrosis. Studies with CsA in cardiac transplant recipients have
shown that renal vascular resistance is elevated, largely because of an increase in
preglomerular resistance. Morphologic changes seen in renal tissue included an occlusive
afferent arteriolopathy with downstream collapse or sclerosis of glomeruli. Ischemic
nephrons were associated with patchy fibrosis of the surrounding interstitium.143 A major
difference between rejection and CsA toxicity is that CsA mainly affects the arterioles,
while rejection attacks the arteries.142
Chronic changes in the glomeruli are often referred to as chronic transplant
glomerulopathy. The central findings are the presence of mesangial interposition in the
capillary basement membrane (double contours), an increase in the mesangial matrix, and
glomerular sclerosis.137 The effect of CsA on glomeruli may be interpreted as an extension
of the arteriolopathy into the glomeruli. The concomitant evaluation of the vascular changes
is important in revealing the etiology of the glomerular changes.142 In animal studies, CsA
has induced glomerulosclerosis.149 In a study by Cosio et al.,150 FSGS was present in 30% of
patients with CR. FSGS correlated with later GS but also with arteriolar hyalinosis, which
led the authors to relate the finding to CsA toxicity.150 Persistent glomerular hyperfiltration
and glomerular hypertension (not necessarily systemic) have been shown to induce
progressive glomerular sclerosis, both in experimental animal models and after long-term
follow-up in nephrectomized individuals.151
The most common lesions in the tubulointerstitial space are mononuclear cell
infiltrates, tubular atrophy and fibrosis.139,142 In well-functioning grafts, 2 years after TX,
Isoniemi et al. discovered diffuse interstitial fibrosis, although mostly mild, with an
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incidence of 62%.139 The interstitial inflammation should not be accompanied with tubulitis,
for that is a hallmark of acute/active rejection.137 Scars (e.g. infarcts, pyelonephritis,
previous biopsies), subcapsular fibrosis (e.g. ischemic damage of the outer cortex due to
interruption of capsular blood flow during TX), and fibrosis without tubular atrophy (e.g.
resulting from persistent interstitial edema after urinary tract obstruction or ATN), must be
distinguished from the typical combination of fibrosis and tubular atrophy seen in long-
term allografts.142 As stated above, CsA-induced microangiopathy may result in tubular
atrophy and fibrosis. Striped or patchy interstitial  (e.g. focal) fibrosis has been regarded as
a feature of CsA toxicity.152 In animal studies, CsA has been shown to induce synthesis of
TGF-ß and collagen and thus to promote fibrinogenesis and directly contribute to the
development of interstitial fibrosis.153 Early detection of interstitial fibrotic processes has
been used to predict later deterioration of graft function. Nicholson et al.154 used
immunostaining for collagen III, measured using a semi-automatic image analysis system,
after TX and found that a fraction of immunostained collagen III with an area of >40% at 6
months was associated with a significantly lower GFR at 24 months.154 Isometric
vacuolization of tubules is a reversible acute side effect of CsA, although not solely specific
for CsA, and is usually related to high doses of the drug.152 However, tubular atrophy with
interstitial fibrosis is nonspecific and by itself allows neither the diagnosis of rejection nor
the diagnosis of CsA toxicity.
In the literature, reports on histopathologic findings in pediatric patients are scarce.
The findings in children with functioning allografts have not been very different from those
in adults. In a study by Laine et al.,124 the most common findings at 18 months were diffuse
interstitial fibrosis (incidence 57%), an increase in the glomerular mesangial matrix (91%),
arteriolar intimal proliferation (70%), and tubular atrophy (83%). Although pathologic
findings were apparent in most of the biopsies, the changes were mild and most biopsies
were scored as normal or borderline according to the BC.124 Broyer et al. found that, 12 to
18 months after TX, 50 to 60% of children already had some changes of chronic allograft
nephropathy in protocol allograft biopsies.155
Risk factors for the development of chronic allograft nephropathy
Since the pathogenesis and treatment of chronic dysfunction are unknown, a number of
epidemiological studies have examined the clinical correlates to its development. Clinical
correlates for chronic renal allograft rejection can be classified into two broad categories:
immune (alloantigen-dependent) and nonimmune (alloantigen-independent). The strongest
immunologic associations are related to AR. However, AR are not uniform, but seem to
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have a different impact on later graft dysfunction, depending on timing, severity, recipient
factors, etc. Putative nonimmune risk factors include donor source, cold ischemia time,
delayed graft function, mismatching of organ size, donor age and disease, donor and
recipient gender, race of the recipient, hyperlipidemia, and hypertension. However, there
has been little evidence supporting a cause and effect relationship between any immune or
nonimmune risk factor and chronic allograft dysfunction.156 Many of the nonimmune risk
factors are interrelated. For example, a longer period of cold ischemia is inherent in CAD
TX and CAD grafts are especially prone to delayed graft function,64 recipient race is
connected with hypertension,157 and so forth. In addition, the immune response may be
influenced by nonimmunologic factors.158
A history of AR episodes has been well established to be a risk factor for later
allograft loss and CR in both adults159,160 and children57,58,161 receiving CsA. However, AR
have not correlated with chronic allograft damage in all studies.139 The AR rates in children
are generally higher than those observed in adult patients.1 In the NAPRTCS study by
Tejani et al.,59 one AR episode increased the risk of CR graft failure three-fold, whereas two
or more AR episodes, when the first was a late initial rejection, increased the risk 26-fold.59
This last study was hampered by the fact that CR was defined as decreasing graft function
and was not based on allograft biopsies. However, multiple AR have been shown to be a
strong risk factor for the development of biopsy proven CR (p < 0.0001, odds ratio 30.1) in
children.57
The irreversibility of AR has been greater in younger children. For LRD transplant
recipients in the age range of 0-5 years, irreversible rejection has been observed in 8.7%,
compared to 4.1% for older children (RR=1.46, p < 0.001). Similar results for CAD
transplants were 12.6% versus 6.6% (RR=1.5, p < 0.001).162 It has been suggested that
young children have a higher immunoreactivity than older children and adults and therefore
a higher incidence of AR.163 However, another possible explanation is that the clinical signs
of AR are subtler in small children and are therefore diagnosed at a later point, when more
tissue damage has occurred. In a study by Their et al.,164 fine-needle aspiration biopsies
(FNAB) were used routinely (i.e. without clinical signs of AR) after TX, 90% of the early-
diagnosed rejections were reversible, and subsequently no allografts were lost on account of
AR.164 In a randomized study by Rush et al., the treatment of subclinical AR, defined by
biopsy and by BC criteria, also led to better histologic and functional outcomes in adult
renal transplant recipients.165
Tullius et al.166 has shown that, at an early stage of the inflammatory process, single
AR episode may be completely reversible and need not progress to CR. Tullius et al. used
acutely rejecting rat kidney grafts that were retransplanted sequentially into syngeneic
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donor rats at different time points. Those grafts that were retransplanted earlier, recovered
completely, whereas those retransplanted at a later stage, showed massive cellular infiltrates
associated with extensive necrosis and were lost. These results demonstrate the critical
effect of alloantigen-dependent events on chronic graft deterioration, and indicate that
prompt and aggressive treatment of initial AR episodes is important, protecting against late
deleterious changes in the graft.166
Ishikawa et al.167 calculated area under the curve for creatinine (CrAUC) as a
quantitative measure of AR. Later graft loss was significantly increased in the group of
patients whose curves showed a rapid rise and a slow fall (corresponding to a greater
CrAUC and presumably a more severe AR).167 In rats, histological changes of CR have
earlier been shown to correlate specifically with CrAUC during AR.168 In a study by
Setterberg et al., CrAUC was a major risk factor for biopsy-proven CR in a case-control
study of 45 adult recipients (blood pressure, blood lipids, and average CsA concentrations
were similar between groups), In addition, the adjusted odds ratio for CR increased
stepwise from 1.1 to 9.2 when CrAUC increased from <150 to >300 µmol/L.169
The timing of AR after TX has also been shown to be important. Patients
undergoing their first AR episode >60 days after TX (vs. ≤60 days) have had an increased
incidence of CR.160 In the literature, the definition of early vs. late has been quite variable.
In the NAPRTCS report by Tejani et al., late AR was defined as >365 days. However, in
this report the late AR also had an increased risk of CR.170
The importance of AR with vascular involvement during the first 3 months after TX
has been shown in one study including 482 CAD recipients. Five-year GS was 73.5% for
the group without rejection, 71.4% for the patients with interstitial rejection, and 34.3% for
the patients with vascular rejection.171
In addition to its nephrotoxicity, inadequate immunosuppression, with either low
doses or trough levels of CsA, is another risk factor for later graft loss and CR, particularly
by enhancing the risk of AR.58,159 This is particularly a problem in connection with poor
patient compliance.136
Ischemia/reperfusion injury has been shown to induce up-regulation and surface
expression of adhesion molecules, activation of circulating host leukocytes, and release of
oxygen free radicals and inflammatory mediators. Increased expression of MCH (major
histocompatibility complex) antigens, making the graft more prone to host attack (e.g. AR)
has also been shown.158
In experimental models in animals different antihypertensive drug treatments have
been used to reveal the extent of influence of hypertension on graft structure and function.
In an experimental model by Paul et al.,172 several treatment regimens decreased systemic
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and glomerular capillary pressures and were associated with improved GS, decreased
proteinuria, and a tendency to improved graft function. Histopathology showed a significant
amelioration of glomerular mesangiolysis and glomerulosclerosis, but no effect was found
on the tubulointerstitial lesions. The angiotensin receptor blocker also inhibited graft
atherosclerosis.172
The leading hypothesis for explaining the inferior GS with size-mismatched grafts
(e.g. a pediatric kidney in an adult, a female donor for a male recipient) has been the
hyperfiltration theory. This postulates that a reduced nephron mass in relation to the needs
of the recipient leads to hyperfiltration of the remaining nephrons. The hyperfiltration leads
to hypertrophy and sclerosis and ultimately to collapse of the overloaded nephrons. The
process is self-perpetuating.173-175 However, the hyperfiltration theory has not been
confirmed in all studies.176
The result of any injury, whether immunologic or nonimmunologic, may be a
reduction of the functioning renal mass.158 Thus, an injury that is primarily immunologic
may lead to a non-immunologic consequence that is detrimental for the graft. Many of the
graft losses attributed to CR may, in fact, be ultimately lost due to hyperfiltration
damage.177
GROWTH
Growth in chronic renal failure
In children with CRF, one of the typical clinical manifestations has been impairment of
linear growth.178 Growth retardation in children with CRF was described as much as two
centuries ago.179
Severe growth retardation is a typical manifestation in many syndromes involving
the kidneys, even in the absence of defined CRF. Primary tubular disorders affecting the
acid/base balance, water, and electrolyte homeostasis lead to growth retardation. The most
severe growth failure is seen in patients with complex tubular dysfunctions such as Fanconi
syndrome.180 Cystinosis is a severe systemic disease involving other organs besides the
kidneys and resulting in remarkable growth retardation.181 Although remarkable growth
retardation is not a major manifestation of NPHS1, the basic problem, severe loss of
protein, leads to protein malnutrition and growth retardation.6 In addition to malnutrition,
loss of immunoglobulins, complement factors, etc. makes the children prone to recurrent
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infections. Loss of carrier proteins (e.g. thyroid-binding globulin) leads to secondary
endocrine alterations that may all affect growth.6
Severe CRF or uremia affects growth in several ways. Uremia causes nausea,
vomiting, and loss of appetite. Betts and Magrath182 reported almost 30 years ago that
children with CRF had significant generalized reductions of energy, protein, and vitamin D
intakes as compared with healthy children. Reduced growth velocity occurred when energy
intake fell below 80% of that recommended.1 8 2  Inadequate nutrition is particularly
devastating in infancy. The infantile growth phase, which starts in intrauterine life and ends
during the second year of life, is mainly dependent on nutrition  in contrast to the childhood
phase, which is influenced by growth hormones (GH) and to the pubertal phase, which is
influenced by sex steroids.183,184 Since final height is mainly gained during early life and
during the pubertal growth spurt, a major loss in relative height occurs during the nutrition-
dependent infantile period.178
The metabolic acidosis inherent in uremia affects growth by causing several
endocrinologic disturbances, particularly affecting the somatotrophic hormone axis.178
Moreover, it has been shown that metabolic acidosis in children with CRF results in an
excessive catabolic state, suggesting that acidosis-related protein wasting may contribute to
growth retardation.185
The kidney plays a major role in bone and mineral homeostasis. It regulates
calcium, phosphorus, and magnesium metabolism, and participates in the catabolism of the
parathyroid hormone. The action of the enzyme 1α-hydroxylase  in the kidney converts 25-
hydroxyvitamin D into 1,25-dihydroxyvitamin D3 (calcitriol). Calcium uptake in the
intestine is regulated by calcitriol. Reduction in calcitriol production leads to hypocalcemia,
which triggers parathyroid hormone secretion leading to secondary hyperparathyroidism.
Renal osteodystrophy is a heterogeneous disorder secondary to hormonal imbalances and
disturbances in mineral metabolism. Renal osteodystrophy invariably affects skeletal
growth and development, leading to bone deformities and deceleration of linear growth.186
Strategies to reduce renal osteodystrophy have basically included phosphate-binding
agents to prevent hyperphosphatemia, and calcitriol or other vitamin D-related substances
(e.g. dihydrotakysterol, alphacalcidol) to prevent hyperparathyroidism.186 Some of the
phosphate-binding agents contain aluminum, which itself induces osteodystrophy.187
Impaired growth does not depend on lack of GH; in fact, endogenous GH levels
have been reported to be high in children with CRF.188 The increased circulating GH levels
are mainly a result of reduced clearance due to impaired GFR.189 GH is carried in the
circulation by GH-binding protein, the main target being the binding to hepatic GH binding
receptors. Reduced GH-binding protein levels have been found in CRF, which in turn is
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correlated with lower expression of the hepatic GH receptors.190 Despite normal or even
high levels of GH, the effect is a state of insensitivity to GH.
The main factor regulating growth is thought to be the bioavailability of insulin-like
growth factors (mainly IGF-1). Circulating IGF-1 is mainly of hepatic origin and a reduced
number of GH-binding receptors in the liver results in suboptimal stimulation of IGF-1
production.191 The bioavailability of IGF-1 is also regulated by certain IGF binding proteins
(e.g. IGFBP-3). GFR has been shown to correlate inversely  with plasma levels of these
IGFBP.192 The reduced clearance leads to an excess of the binding proteins that bind IGF-1
and the biological action of the IGF on growth plate cartilage is thus inhibited.193
Consequently, both reduced production and increased binding of IGF-1 reduce its
bioactivity.
Anemia has been considered to have an effect on growth, but a study by Rees et al.
failed to show any beneficial effect on longitudinal growth following erythropoetin
treatment in children with CRF.194
Today, it is possible to reduce some of the growth impairment by aggressive
treatment of the complications caused by uremia, particularly by enhancing nutrition in
early childhood195 and commencing dialysis treatment.196,197 In the NAPRTCS report on
chronic dialysis in children, the baseline mean height standard deviation scores (hSDS) in
children <2 and between 2–5 years of age were -1.97 and -2.25. After 2 years on dialysis,
the corresponding values were -2.44 and -1.92, i.e. a deceleration in the youngest age
group.8 However, the mean height deficit in children at the time of TX has diminished,
being -2.2 in 1987 and -1.76 in 1996. In some of the age groups this is probably partly due
to improvement of dialysis management, but the preTX use of GH has also had an impact.3
Growth after renal transplantation
TX corrects the uremia and should provide better conditions for normal growth. However,
in the majority of pediatric recipients, standardized height (z score or hSDS) does not
improve and may even worsen  following TX.198
Catch-up growth occurs primarily in recipients <6 years of age at TX.198
Consequently, many centers have reported catch-up growth after TX in children <5 years of
age.44,54,199,200 In the large registry report of NAPRTCS, catch-up growth after TX was seen
only in the youngest age groups.3 The mean hSDS at TX was -2.57 and -2.58, in children
<2 years and 2-5 years, respectively. Five years after TX, both groups had improved their
mean hSDS to -1.69 and -1.76. In contrast, in the age group 6-12 years, their hSDS had
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worsened from  -2.17 at baseline to -2.49 at 5 years and in the age group 13-17 from -1.70
to -2.19.3
CS have numerous immunosuppressive and anti-inflammatory effects and have
been used in the majority of children after renal TX. Their interference with growth has
probably been the most worrisome side effect.35 Pharmacological doses of glucocorticoids
interfere with the integrity of the somatotrophic hormone axis at different levels. The
majority of patients on chronic CS medication present with overt GH hyposecretion,
apparently due to enhancement of hypothalamic somatostatin release. Glucocorticoids also
inhibit IGF bioactivity by the induction of IGF inhibitors and stimulate the production of
certain IGFBP. In addition, glucocorticoids inhibit growth directly at the tissue level by
suppressing local growth factors and skeletal tissue matrix production,201 decreasing
osteoblastic bone formation and increasing bone resorption.202
Several strategies have been used to cope with steroid-induced growth retardation.
Growth is significantly more retarded with high doses of CS than with low-dose
administration.203 Alternate-day CS treatment improves linear growth, but is not effective in
all children.204,205 Cessation of CS treatment has been advocated in children with stable graft
function, but the authors have not recommended routine discontinuation because of the
high incidence of AR.34,206 In children with stable graft function and CsA treatment,
Reisman et al.206 have reported an AR rate of 56% after cessation of low-dose maintenance
steroid treatment.206 In a study by Chakrabati et al.,207 steroids were successfully withdrawn
in 70% of children receiving tacrolimus-based immunosuppression, but had to be restarted
in 22.5% of children (7.5% were never taken off steroids). The latter group had patient
survival and GS rates comparable with those off the group that were off steroids, but had a
higher serum creatinine level and a higher incidence of AR.207 Birkeland has reported more
promising results in both adults and children with a steroid-free protocol including CsA and
mycophenolate mofetil as maintenance immunosuppression. The author suggests that
avoidance of steroids from the beginning lowers the risk of acute rejection as compared
with cessation of a steroid-adapted immune response.208
Studies in both adults and children suggest that secondary hyperparathyroidism (the
most frequent type of renal osteodystrophy) and increased bone remodeling activity may
persist for months after TX. The severity of secondary hyperparathyroidism prior to TX, the
duration of dialysis, and the development of nodular and/or monoclonal hyperplasia of the
parathyroid glands are the most important factors determining this phenomenon.121
Immunosuppressive agents other than CS, especially the calcineurin-phosphate inhibitors,
also independently exert a negative effect on bone by increasing bone resorption and
formation.202
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Graft function inevitably deteriorates  with time after TX. Growth is affected by the same
mechanisms as in CRF, the decreased GFR leading to excess of IGFBP and reduced IGF
bioactivity.191 Hokken-Koelega et al have shown that a GFR persistently reduced below 50
mL/min/1.73 m2 significantly affects growth in prepubertal children after TX.209
The height deficit at the time of TX has been shown to be correlated with the height
increment following TX.198 In a study by Hokken-Koelega et al.,209 prepubertal children
with the most severe growth retardation at TX had the most pronounced growth spurts after
TX. However, 2 years after TX they were still shorter than those with less severe growth
retardation at TX.209
The question still arises: do children, although they experience catch-up growth,
reach target adult height? Patients with CsA in combination with low-dose prednisolone
have been shown to have a better prognosis for final height than children with Aza and
steroids. However, target heights could not be achieved in any group.210 In a report by
Hokken-Koelega et al., up to 77% of patients who received their first renal transplant
before the age of 15 ended up with severely short adult stature.211 In a report by Offner et
al., final height was stunted in 44% of noncystinotic patients.181 In a report by Rodriguez-
Soriano, the final hSDS was below the 95% confidence limits for target height in 41% of
children transplanted before the age of 15, even though some of the patients had been
treated with GH.212
Growth hormone treatment in chronic renal failure and after renal transplantation
GH treatment with recombinant human GH has improved growth significantly in children
with CRF213,214 and after TX.215-217 Children on dialysis seem to respond significantly less
than children receiving conservative treatment with CRF.218 GH treatment is effective,
inducing catch up growth even during puberty.219
In some patients, the effect of GH treatment seems to persist after discontinuation of
treatment. Fine et al. have shown that a pause in GH treatment in children with CRF after
attainment of target height leads to maintenance of hSDS in 27% and a marked reduction in
growth velocity in 73%, requiring reinstitution of GH therapy.220 Discontinuation of
treatment at the time of TX does not result in substantive deterioration of growth.220
Reports on long-term follow-up with GH therapy have shown that target height can
be reached in a substantial number of children with CRF.221,222 Haffner et al.223 have studied
long-term growth in children with CRF enrolled when receiving conservative treatment.
The majority of patients were switched to dialysis and subsequently received renal
allografts during follow-up. Thirty-eight children treated with GH improved their mean
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hSDS by 1.4 SDS to a mean final adult height of -1.6 ± 1.2. Although 65% of the children
reached an adult height within the normal range, the mean final adult height was below the
genetic target height by 10.1 cm in boys and 12.1 cm in girls. However, fifty controls not
receiving GH, who were followed into adulthood, decreased their hSDS from baseline with
a mean of 0.6 SDS to a mean final adult height of -2.1 ± 1.2.223
Exogenous GH treatment improves growth, even though there is usually no lack of
endogenous GH.188 Treatment with GH increases IGF-1 concentration and normalizes IGF-
1 bioactivity in children with CRF (see earlier section on growth in CRF).224 Some authors
have recommended that GH treatment should be started at a young age, and early in the
course of CRF.225
CS influence growth in a multifactorial way (see the earlier section on growth after
TX) but GH can counteract some of these negative effects on growth after TX.201 However,
in several studies, CS has still influenced the response to GH therapy on growth
negatively,226,227 although not in all.201 Age, renal function, pretreatment height velocity, and
the degree of stunting have also been variable as predictors of the response to GH
treatment.201,227
Opinions about the safety of GH treatment have been controversial.228,229 The key
issue in the discussion is the possible side effects after TX. GH treatment during CRF has
not caused any later influence on GS or incidence of AR in subsequently transplanted
children.230 GH treatment may carry the risk of immunoactivation.231,232 In a French
multicenter study with long-term GH use, the risk of rejection was shown only in children
with a prior history of more than one rejection episode.215 Laine et al. reported no increased
incidence of AR.233
In normal subjects, exogenous GH increases GFR and RPF.234 Beside the possible
effect of inducing AR, long-term graft dysfunction can occur as a result of glomerular
hyperfiltration leading to glomerulosclerosis. In a study of GH use after TX by Maxwell et
al., GFR improved for up to 6 months, but had returned to baseline by 1 year after TX.235
Many studies have reported a deterioration in graft function related to the use of GH after
TX,231,236,237 but the results are hampered by the fact that loss of graft function is usually
inevitable after TX. In studies where matched control groups have been used, there has
been no clear effect of GH on graft function.215,233
Although prepubertal bone maturation was accelerated in GH-treated children with
CRF, treatment was not associated with a shortening of the pubertal growth spurt.223
Growth potential was not adversely influenced in long-term (5 years) treatment of 20
growth-retarded pre-pubertal children with CRF.222 In the majority of reports after TX,
growth occurred without accelerating skeletal maturation and without advancing pubertal
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status.216,237,238 However, there may be substantial intra- and inter-observer variability in the
assessment of bone age (BA) which may hamper the interpretations.239
Avascular necrosis of the femoral head and intracranial hypertension have been
reported in connection with GH use.229 Impaired glucose tolerance with increasing insulin
levels has been reported, but this has also been reported in control groups without GH
treatment but with concomitant steroid treatment.215
Factors affecting growth are summarized in Figure 1. Many of the factors are
interrelated and age, particularly, has an impact on many of them (e.g. the importance of
nutrition in infancy).
Figure 1. Major factors affecting growth in chronic renal failure and after transplantation in children.
Review of the literature
40
NEURODEVELOPMENTAL OUTCOME
Children with a severe renal disease from birth are vulnerable to neurologic complications,
and the first reports in the literature on children with CRF from birth were extremely
disappointing.240,241 Progressive encephalopathy with characteristic clinical features and
electroencephalogram (EEG) findings have been described in both children with untreated
CRF and in patients on dialysis.240-242 In a report by Rotundo et al., the encephalopathy was
characterized by developmental delay, microcephaly, hypotonia, seizures, dyskinesia, and
EEG abnormalities.241 The unfavorable outcome of neurologic development is presumably a
condition with multifactorial etiology resulting from the toxic effects of uremia,
malnutrition, and aluminum toxicity and from the psychosocial complications associated
with a severe chronic illness.240,243 Thus, in very young children a less favorable
developmental prognosis may be expected with early onset of renal disease and longer
duration of end-stage renal failure.244,245
TX has subsequently been shown to improve the neurodevelopmental outcome and
to ameliorate many of the adverse effects of CRF.244-247 Although kidney function is
restored after TX, some of the perturbations in the developing brain connected with  CRF
and its complications may not be reversible. Neurodevelopmental outcome after TX must
therefore be viewed as also incorporating  the pre-TX history. Risk factors for an impaired
neurodevelopmental outcome are listed in Table 5.
Table 5. Risk factors for an impaired
neurodevelopmental outcome
in chronic renal failure.
Disease-specific
Other organ (e.g. brain) manifestations
Hypercoagulability (e.g. NPHS1)
Prematurity
Age
Nutrition
Uremia
Multifactorial etiology
Aluminum toxicity
Hypertension/hemodynamic crises
Seizures
Severe infections
Chronic severe illness/hospitalization
Drugs
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Complications and risk factors for an impaired neurodevelopmental outcome
The most common neurological complications seen in adult renal transplant recipients are
cerebrovascular events.2 4 8  The risk of these increases with age and is not a major
complication in children after TX.3 There are few studies in which neuroradiology has been
investigated routinely after renal TX. In most reports, neuroradiologic studies have only
been performed on clinical indications.
Arterial border-zones are specific regions of the brain that, for anatomical reasons,
have a reduced number of collaterals and are therefore most vulnerable to the ischemia
caused by hypoperfusion, in situations such as systemic hypotension, micro-embolism or
severe carotid stenosis.249 Watershed or border-zone infarcts can be divided into subtypes:
superficial watershed infarcts located between the vascular territories of the main cerebral
arteries (e.g. anterior and middle cerebral artery and posterior and middle cerebral artery)
and internal junctional infarcts in the area between the deep perforators and the superficial
branches of the middle cerebral artery.250 Mounier-Vehier et al. have proposed that the
subtypes of border-zone infarcts may be caused by different mechanisms. Heart disease was
more frequent in the group with internal junctional infarcts and arterial hypertension and
internal carotid artery stenosis were more frequent in the group with superficial watershed
infarcts.251
Brain atrophy has been reported in up to 60% of children with CRF, including
patients undergoing dialysis treatment and after TX.252-254 Elzouki et al.255 have reported a
prevalence of 23%, and the authors attribute the improved neurological outcome to the
policy of avoiding aluminum therapy and giving vigorous nutritional support.255
Children with NPHS1 also have a severe coagulation abnormality during nephrosis,
due to urinary loss of plasminogen and ATIII and compensatory protein synthesis leading
to elevated levels of such substances as macroglobulins and fibrinogen, thus leaving them
prone to for cardiovascular insults.6 Hypercoagulability has also been documented in
children on chronic peritoneal dialysis, regardless of the underlying disease.256
In epidemiological studies, by far the most important risk factor for stroke is
hypertension.101 Apart from enhancing atherosclerosis, it causes adaptive structural changes
in the cerebral vasculature that lead to increased peripheral resistance and reduced collateral
capacity. These changes, in turn, reduce the autoregulatory capacity of the small arteries
and arterioles in the event of an abrupt drop in blood pressure.257 Hypertensive
encephalopathy is considered to result from breakdown of the autoregulatory capacity of
the arterioles, especially in the posterior watershed regions at times of systemic blood
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pressure elevation, leading to vascular dilatation and vasogenic edema.258 The condition is
usually reversible but, in severe cases, may lead to secondary ischemia.259
Severe arterial hypertension is also often associated with seizures.254,260,261 In a report
by McEnery et al., seizures occurred in 31% of children, either before or after TX.261 In a
report by Awan et al., 18% had had documented seizures after TX and 5% required
anticonvulsive treatment after TX.260 In the NAPRTCS report of 1997, 6% of LRD
recipients and 10% of CAD recipients had anticonvulsant therapy after TX.3 Children who
have seizures after renal TX usually have a good prognosis and a good long-term
neurologic outcome.261
Infections are the leading cause of mortality after TX in children.3 Severe infections
and septic shock with organ failure, and respiratory and cardiovascular complications may
also lead to permanent neurologic sequelae. Children with NPHS1 are prone to infections
during nephrosis, mainly because of loss of gamma globulin and complement factors.6
Hearing loss is frequent in renal diseases. Certain types of hearing loss are
particularly common in pediatric patients with renal disease. Bergstrom et al prospectively
followed 151 patients with renal TX, 47% of whom had hearing impairment. Certain types
of hearing loss, e.g. ototoxic, genetic and congenital, were particularly frequent in young
children.262 Mancini et al263 documented sensorineural hearing loss (SNHL) in 38% of
children with CRF in childhood. The use of ototoxic drugs was one risk factor and
congenital nephropathies were also shown to carry an increased risk of SNHL compared
with acquired diseases.263 An endogenous toxic effect relating to uremia has been proposed,
particularly causing the hearing loss related to high frequency.264 Hearing loss has also been
reported after administration of various immunosuppressive drugs, including CsA.265,266 The
etiology of SNHL is usually the combined result of many factors.267
The degree of hearing disability or handicap has been reported as 8% in the EDTA
registry report including both dialysis and TX patients.268 In a single center report by
Mancini et al., the use of hearing aid was required by 9% of patients with CRF.263
Aluminum intoxication is an iatrogenic disease caused by the use of aluminum
compounds for phosphate binding and by contamination with parenteral fluids (e.g.
dialysis). Aluminum toxicity has been shown to cause encephalopathy, metabolic bone
disease, and microcytic anemia.269 Excessive oral aluminum intake is probably of central
importance as a cause of aluminum toxicity, particularly in infants.187 Severe neurologic
complications, such as encephalopathy, were reported in the 1980s in relation to the oral
intake of aluminum and CRF.243 Subsequently, many reports have attributed, an improved
neurodevelopmental outcome in CRF, at least in part, to avoiding aluminum, although this
aspect has not been specifically studied.255,270
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Children with NPHS1 are often born prematurely (on average at the 36th week) with a
correspondingly low birth weight.6 The main feature of NPHS1 is the massive early
proteinuria, and the major clinical problems are secondary to hypoproteinemia and not to
the slight prematurity.6
CsA is potentially neurotoxic. In a study by Grimm et al., a decline in cognitive
performance in a series of heart transplant patients was related to the cumulative dose of
CsA.271 Schwartz et al.272 performed computed tomographies (CT) and magnetic resonance
imaging (MRI) on patients who had  neurologic findings attributed to CsA therapy, and
found that the radiologic appearance was identical to that seen in hypertensive
encephalopathy.272
School and cognitive performance
In the EDTA registry report, 16% of children who had had renal replacement therapy had
entered special schools for the handicapped.273 Davis et al.274 have reported on the long-term
educational status of children with renal insufficiency since infancy. In that report, 76%
attended full-time regular classrooms and 14% attended full-time special classrooms.274
Brouhard et al.275 have published a multi-center report on 63 children who had end-stage
renal disease and 62 sibling controls. Most patients (61%) and siblings (84%) were in
regular school classes, and most (87% and 92%, respectively) attended school full-time.
The average intelligence quotient (IQ) and the scoring on achievement tests were
significantly lower for the patients than for their siblings. Patients´ scores on achievement
tests were influenced by age at diagnosis and by the mother/caregiver's lower achievement.
Increased time on dialysis also predicted lower scores in achievement tests. Neither dialysis
or transplant status nor ethnicity significantly affected the outcome.275
The results of peritoneal dialysis treatment given to infants have improved and
although the mortality rate is still high, particularly because of co-morbidity, the survivors
show a superior neurodevelopmental outcome compared with historical controls. In a report
by Ledermann et al., 14 of 16 survivors has achieved normal developmental milestones or
attended mainstream school.197 In another report by Warady et al., 94% of children who had
had peritoneal dialysis in infancy attended school full time and in age-appropriate
classrooms.270 In a prospective report on pre-school children with CRF, after starting
dialysis the effect on cognitive performance appeared to be positive, but only a significant
short-term improvement was observed. Follow-up evaluation of 9 patients undergoing
dialysis over a 2-year period did not show any significant change in a positive or negative
direction.276 Lawry et al.277 found no differences between patients undergoing dialysis and
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after TX in overall IQ and subtest scores, but performance on achievement tests was better
in the TX patients. Furthermore the patients undergoing dialysis tended to be below the age
and grade level in all areas, whereas the patients with transplants were achieving at or
above these levels.277
Psychological problems have been reported significantly more often in children
during peritoneal dialysis than after TX. However, both psychological problems and school
problems were significantly greater in both dialysis and TX patients as compared with
healthy controls.278
Cognitive performance has been shown to improve, in both adults and children,
without major neurologic difficulties before TX.246,247 Several reports have suggested that in
most infants with severe impairment due to CRF, a successful TX improves psychomotor
development.200,244,279,280 However, major handicaps affecting cognitive performance will, of
course, persist even after a successful TX.
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AIMS OF THE STUDY
Young age is still considered a risk factor for inferior patient survival and GS in pediatric
TX. Although survival rates have improved, long-term graft function, growth, and
neurodevelopmental outcome have not been extensively studied in this high-risk group of
patients. There is a relative abundance of young children under the age of five years
receiving a kidney graft in Finland, on account of the high incidence of the congenital
nephrotic syndrome. Thus, we have not only a good opportunity, but also a certain
responsibility to assess the overall long-term outcome of these young children.
The aims of the study were to investigate the outcome (up to 7 years) after TX in children
who received transplants when under 5 years of age. Infants <2 years of age at TX were
compared with those 2-5 years of age at TX, with particular emphasis on:
1. Graft function
2. Renal allograft histopathology
3. Growth
4. Neurodevelopmental outcome at school age
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PATIENTS AND METHODS
ETHICAL CONSIDERATIONS
The study design was approved by the Ethical Committee of the Hospital for Children and
Adolescents, University of Helsinki, and informed consent was obtained from parents or
patients prior to their inclusion in the study.
PATIENTS
Fifty-nine children under the age of 5 years when they received their first renal graft had,
by the end of 1999, received 65 grafts at our center. The most common disease (48 patients,
81%) was NPHS1.4 Other diagnoses were a urethral valve and polycystic kidney disease in
3 patients each, prune-belly syndrome in 2 patients, and hyperoxaluria, neuroblastoma, and
congenital nephropathy, each in 1 patient. Twenty-one children (36%) were girls and 38
(64%) boys; 53% of the patients received grafts before the age of 2 years. Forty-one CAD
TX were performed (63%, including 6 regrafts). All these patients are included in the
patient survival and GS rate calculations presented in this thesis.
Study I (long-term graft function) included all 49 recipients of a first kidney
allograft at less than 5 years of age transplanted between 1987 and 1997. All these patients
were seen every 3-6 months at our center during the first 2 years and subsequently
annually. Forty-three patients were followed for at least 1.5 years. Clearance investigations
were only started in 1990 and were thus not performed at 18 months on the earliest patients.
The patients were basically the same in study II (long-term histopathology).
Prospective follow-up of renal histology was started in 1990 and therefore a biopsy
specimen was not available from the first five patients at 18 months. Biopsies were not
taken (either for clinical reasons or refusal to participate) from three additional patients at
1.5 years, from one patient at 3 years, from three patients at 5 years and from one patient at
7 years.
Forty-three of the patients had a functioning graft and a follow-up of at least 3 years
after TX. Two of them had only received GH treatment prior to TX and were excluded
from analysis in the prospective study of long-term growth (study III). Thirty-two patients
had a follow-up of at least 5 years and 26 of at least 7 years.
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Only one of the 59 children died before school age. This patient died 3 months after TX at 3
years of age. Thirty-four of the children, transplanted between 1987 and 1995, were of
school age, and were investigated for neurodevelopmental outcome at a mean of 6 years
after TX (mean age 8 years, range 7-12) (studies IV and V). One patient with no
neurological risk factors and normal development (according to the medical records)
refused to participate in these studies. Thirty-three patients were thus included in the studies
IV and V. Demographic data for the patients included in the different studies are shown in
Table 6.
Table 6 Demographic data of patients included in studies I to V.
I II III IV-V
Patient number at baseline 49 51 41 33
Diagnosis (NPHS1a/other) 41/8 43/8 36/5 29/4
Gender (male/female) 31/18 32/19 25/16 22/11
Donor source (CAD/LRD) 29/20 31/20 22/19 16/17
Age at first TX (mean ± SD) 2.3 ± 1.1 2.3 ± 1.0 2.3 ± 1.0 2.4 ± 1.1
(range) (1.1-4.5) (1.1-4.5) (1.1-4.5) (1.2-4.5)
Time on dialysis (years) 1.0 ± 0.7 1.1 ± 0.8 1.0 ± 0.7 1.3 ± 1.2
(range) (0.2-3.8) (0.3-3.8) (0.2-3.8) (0.2-3.8)
Donor age (years) (29.4 ± 12.9) 29.9 ± 13.2 30.4 ± 11.5 30.2 ± 12.4
(range) (1.0-55.0) (1.0-55.0) (4.9-55.0) (1.0-55.0)
Cold ischemia timeb (hours) 23.7 ± 6.6 23.3 ± 6.3 21.9 ± 5.3 23.3 ± 6.5
(range) (14.3-40.0) (14.3-40.0) (14.3-37.5) (14.3-40.0)
AB mismatch (mean ± SD) 1.4 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 1.4 ± 0.7
(range) (0-3) (0-3) (0-3) (0-3)
DR mismatch (mean ± SD) 0.7 ± 0.5 0.7 ± 0.5 0.6 ± 0.5 0.6 ± 0.5
(range) (0-1) (0-1) (0-1) (0-1)
aAbbreviations used in the table: NPHS1, Congenital nephrosis with mutations in the nephrin gene; TX,
renal transplantation; CAD, Cadaver donor; LRD, Living related donor.
bOnly CAD recipients
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METHODS
Preoperative management and treatment protocol
ABO compatibility and a negative T-cell crossmatch were prerequisites for TX. A
maximum of three mismatches, with a maximum of one each in HLA-A, -B and -DR loci,
was accepted. All LRD grafts were from one or other parent. Three donor-specific
transfusions (3 mL/kg whole blood each) were given under Aza (1 mg/kg/day) protection at
2-week intervals to recipients of LRD grafts. TX was performed within 2 weeks of the last
transfusion. LRD graft recipients who had received multiple transfusions in early infancy
were not given donor-specific transfusions in order to avoid further antigen exposure. CAD
graft recipients received three random transfusions. Children with NPHS1 were
nephrectomized bilaterally in order to normalize protein and coagulation status, nutrition,
and sensitivity to infections prior to TX. All the children were on peritoneal dialysis for at
least 3 months before TX.
During nephrosis, the NPHS1 children received 130 kcal/kg of energy and 4 g/kg of
protein per day orally (in addition to i.v. substitution of albumin). Nutrition was given as
infant milk and cereal formulas supplemented with a casein-based protein product and
glucose polymers to reach the high target energy and protein intake. During peritoneal
dialysis, the target for daily energy intake was 110% of the recommended daily allowance
for healthy children of the same age. The mean protein intake during dialysis was 2.5 g/kg
per day (140% of the recommended daily allowance). In most patients, nasogastric tube
feeding was used to ensure adequate energy and protein intake.
Other details of pretransplant treatment of NPHS1 patients have been reported in
detail previously.6 Only children with a weight of over 9 kg and without a major
neurodevelopmental illness were accepted for TX. The grafts were placed extraperitoneally
in the right iliac fossa. Iliac arteries and veins or the abdominal aorta and the inferior caval
vein were used for anastomosis. Urinary tract continuity was restored with an open
ureteroneocystostomy.
Immunosuppression
Triple immunosuppression, including, CsA, Aza and methylprednisolone (MP) was used in
all patients. CsA was started pre-operatively with an individual pharmacokinetically
determined dose aiming at a trough blood concentration of 300 µg/L (specific monoclonal
radioimmunoassay, Sandimmun Kit®, Sandoz) at TX.281 MP (100 mg i.v. in three doses)
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and Aza (1.4 mg/kg i.v. in two doses) were given intraoperatively. Post-operative
immunosuppression included; 1) MP 1mg/kg/day, which was tapered down to 0.25
mg/kg/day at 3 weeks and to 0.37 mg/kg/ every other day, (A 25% reduction of the
previous daily dose) after 3 months; 2) Aza 2 mg/kg/day, which was reduced to 1
mg/kg/day after 2 weeks and increased to 1.4 mg/kg/day after 3 months (when the steroid
dose was reduced) and; 3) CsA, which was kept at a trough blood concentration of 300
µg/L immediately after TX and between 60 to 100 µg/L after 6 months. CsA was given in
three daily doses to preschool children because of their faster CsA metabolism.281 We
considered hyperuricemia and hyperkalemia to be markers of early CsA nephrotoxicity in
patients with good graft function and we continuously adjusted the CsA trough blood levels
according to this, renal function, and histology.26,27
Acute rejection
FNAB were taken routinely on the 5th day after TX and at least twice a week until the
patient was discharged from hospital. FNAB were also taken if an AR was suspected on
clinical grounds. AR was defined as fever, an increase in serum creatinine concentration, a
total corrected increment higher than 3.0, and a blast cell increment of at least 1.0 in a
FNAB.282 AR were treated with 1.5 mg/kg of oral MP, followed by 3 mg/kg/d of MP
divided into four oral doses for 5 days or until the blast cell reaction subsided. If no
response was seen after 5 days, a renal core biopsy was performed, and polyclonal anti-
thymocyte globulin or monoclonal anti-T-cell antibody (OKT3) was used if AR was still
present.
Renal function (I)
Kidney function was investigated prospectively 1.5, 3, 5, and 7 years after TX. GFR was
measured by 51Cr-EDTA clearance (ClEDTA). Any results with a distribution space that
deviated by more than 10% from the expected extracellular volume were ignored. Effective
RPF was estimated by para-aminohippuric acid clearance (ClPAH). ClLi and sodium clearance
(ClNa) were measured simultaneously with ClEDTA and ClPAH, as previously described.25 The
measured clearances were corrected for a standard body surface area of 1.73m2 or
expressed as absolute values (mL/min). Urinary concentrating capacity was investigated by
measuring urine osmolality before and 1, 3, and 5 hours after nasal administration of
desmopressin (Minirin®, Ferring, Sweden, dose 20 µg). Values below 750 mosm/kg were
considered subnormal.283 Hyperkalemia was defined as serum potassium >5.3 mmol/L or
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use of potassium-binding medication. A TTKG value below 6.0 (normal median for
children),284 together with hyperkalemia was considered pathological. Hyperuricemia was
defined as a serum urate concentration >330 µmol/L. Urinary protein excretion <250
mg/m2/24h was considered normal.
Calculations
Filtration fraction: FF = ClEDTA / ClPAH
Fractional excretion of sodium: (FeNa) (%) = 100 x ClNa / ClEDTA
FPR (%) = 100 x (1-ClLi / ClEDTA)
TTKG = (K)(urine) / (Urine osmolality / serum osmolality) / (K)(serum).110
Renal histopathology (II)
Percutaneous needle biopsies of the renal core were performed under ultrasound guidance,
using an automated punch device (Biopty-Cut®, Radiplast, Bromma, Sweden). A needle
with an outside diameter of 1.2 or 1.6 mm was used to obtain biopsies 0.9 x 20 mm in size.
The specimens were fixed in 4% formaldehyde, embedded in paraffin, and cut into serial
sections at 4 µm. The sections were stained with hematoxylin and eosin (H&E), periodic
acid-Schiff (PAS), Masson´s trichrome, and methenamine silver PAS for light microscopy.
The biopsies were coded and examined by two investigators independently without
knowledge of kidney function or time of TX. Biopsies with a minimum of five glomeruli
and an artery were considered representative and accepted for analysis. On these criteria, 29
(83%) of the 35 biopsies were suitable for analysis at 1.5 years after TX. The corresponding
figures were 30/35 (86%), 25/26 (96%) and 13/14 (93%), 3, 5, and 7 years after TX,
respectively. The mean GFR of all the patients excluded was 76.0 ± 21.9 ml/min/1.73m2 at
1.5 years, and 82.0 ± 31.8, 59.7 ± 19.1, 49.1 ± 15.4 at 3, 5, and 7 years, respectively. The
GFR of these patients did not differ significantly from those in the study. The mean number
of glomeruli in the analyzed biopsies ranged from 12 to 18, at different time points.
Adequate clinical data were not available for one patient at 18 months and one patient at 7
years at the time when the biopsies were taken, and those two patients were therefore
excluded from the functional and clinical correlations.
The BC (1991) was used for diagnosis and grading of chronic allograft nephropathy
and any signs of AR and CsA-associated changes.135 The histological findings were also
scored semiquantitatively, using our more extended scoring table (II) and the CADI score
was calculated.139 The interstitial changes were classified as focal (less than 2 of 4 visual
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fields) or diffuse. The glomerular changes were scored separately for either segmental or
global changes. Global glomerular sclerosis was also noted separately as a percentage of
the total number of glomeruli examined in each biopsy slide (percentage of sclerotic
glomeruli, PSG). Changes in arteries, arterioles, and veins were scored separately, as were
proximal and distal tubules. The histopathologic changes in our patients were mostly very
mild. Because of this, we used a scale from 0 to 6 instead of 0-3, as in the original paper.139
Thus, 0=no changes, 1=very mild, 2=mild, 3=mild to moderate, 4=moderate, 5=severe,
6=very severe. The CADI was calculated as the sum of the scores of diffuse interstitial
inflammation and fibrosis (0-6 each), mesangial matrix increase, and glomerular sclerosis
(0-6 each), intimal proliferation of vessels (each score for arterial, arteriolar and venous
changes was divided by 3, thus vessels together scored 0-6) and tubular atrophy (each score
for proximal and distal tubules was divided by 2, thus tubules together scored 0-6). With a
scale from 0-6, the total range for the CADI was 0-36.
Growth (III-V)
The children were investigated for growth, BA, and renal function before leaving the
hospital after TX (0 year), and subsequently at 1, 1.5, 2, 3, 5 and 7 years after TX.
Height was measured at noon by the same trained observers, using a Harpenden
stadiometer or a recumbent infant length board for children <2 years of age. The hSDS (i.e.
the z -score) was calculated according to the following equation: hSDS = (observed height
– mean height for age / SD), where SD represents the standard deviation for the normal
population of the same chronologic age and gender.285 Growth velocity was defined as the
rate of change in hSDS during follow-up (∆hSDS). A positive value indicates catch-up
growth and a negative value deceleration of growth.
Weight was determined at noon by the same trained observers, using an electronic
scale. The weight-for-height index (W/H), expressed as a percentage, was determined from
the ratio of weight (kg) to height (cm) to the mean W/H in the normal population of the
same chronologic age and gender.285 A value between –15% and +20% was regarded as
normal.
Occipital-frontal head circumference measurements were obtained before initiation
of dialysis, during dialysis, and after TX at the latest visit, and were expressed as standard
deviation scores (SDS).285
BA determinations, made by the same observer (E.M.) according to the Greulich-
Pyle method, were related to bone maturation in normal Finnish children.286 Height for bone
age (hBA) was also calculated and expressed as a standard deviation score.285 BA
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determinations were not available for 11 patients at TX, or for 5 patients at 1, 2, and 3 years
after TX, respectively. All the patients were assessed for BA at 5 and 7 years after TX.
The mean genetic target hSDS for the children based on parental height
measurements was 0.1 ± 0.5 for children without GH and  –0.4 ± 0.5 for the children
receiving GH therapy.
Eleven of the 41 patients (27%) were treated with daily subcutaneous injections of
GH. GH was started at a median time of 2.2 years after TX (range 1.0-6.0) if height was
below -2 hSDS or height velocity was below the 25th centile. Other prerequisites for
starting GH treatment after TX were a GFR of over 20 mL/min/1.73m2, normal thyroid
function, and no malignancy. The mean duration of the treatment was 5.5 (1.9-8.3) years.
Neurodevelopmental assessment (IV-V)
A single investigator under the supervision of a senior pediatric neurologist conducted all
the neurological examinations. The assessment was modified from a neurodevelopmental
examination used at our center for neurodevelopmental follow-up studies.287 Patients, when
at school, were assessed at a mean age of 8 years (range 7-12). The items were scored
according to Table 1 in study IV; the highest possible score (i.e. maximum impairment) for
each patient was 44.
MRI of the brain was performed in all patients. The patients were all in stable
clinical condition at the time of the MRI studies. During 1993-1997, the MRI studies were
performed with a 1 T (tesla) unit (16 patients). We used T2- and proton density weighted
axial and coronal spin echo sequences and T1-weighted axial and sagittal spin echo
sequences. After 1997, the studies were performed with a 1.5 T unit and the proton density
weighted images were replaced by an axial FLAIR (fluid attenuated inversion recovery)
sequence (17 patients). Two patients had two studies, one with each MRI unit. No
intravenous contrast agent was used. Pre-TX CT studies of 26 patients were available for
comparison. The studies were analyzed by a pediatric neuroradiologist and a pediatric
neurologist, blinded for the detailed clinical history and outcome of the patients. All
findings and their locations were recorded and a particular analysis of the main findings
was made according to the following criteria: Ischemic lesions were divided into those in
the main vascular territories and those within the border-zone regions, and scored as mild
(grade 1), moderate (grade 2) or severe (grade 3). Atrophy was recorded as mild, moderate
or severe, central or cortical, and cortical atrophy was evaluated separately in each lobe.
EEG recordings were taken, using digital Nervus recorders by Taugagreining hf.
The international 10-20-electrode system was used. EEG were performed prospectively (i.e.
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not in connection with or after a seizure) with standard techniques, including intermittent
photic stimulation and hyperventilation. Recordings were not available for 2 patients. One
of them had no history of seizures; the other had had one seizure during dialysis, but no
seizures or anticonvulsive treatment after TX.
Pure-tone audiometry was performed in all but 3 patients. Prior to audiometry, the
ear status was inspected by an ear, nose, and throat specialist to exclude cases with fluid or
significant negative pressure in the middle ear. Air- and bone-conducted thresholds were
examined at frequencies from 0.25 to 8 kHz with a Madsen OB-70 or OB-822 diagnostic
audiometer, employing TDH-39 headphones. According to the proposal of the European
Union Working Group,288 the degree of hearing impairment was defined as mild when the
BEHL (better ear hearing level, averaged over the middle frequencies 0.5,1,2 and 4 kHz)
was 20 dB< x <40 dB, moderate 40 dB  < x <70 dB, severe 70 dB  < x <95 dB, and profound
>   95 dB. The type of hearing loss was conductive when the bone conduction thresholds
were normal (<20 dB) and there was an air-bone gap  >15 dB averaged over 0.5, 1, and 2
kHz, whereas the type was mixed when a similar air-bone gap was combined with elevated
(>20 dB averaged over 0.5, 1, and 2 kHz) bone conduction thresholds. The impairment with
an air-bone gap <15 dB averaged over 0.5, 1, and 2 kHz was defined as SNHL.
Verbal and non-verbal IQ were estimated using the revised version of the Wechsler
Intelligence Scale for Children (WISC-R).289 IQ levels ranged from <70 (mentally
deficient), ≥70 to <90 (borderline-low average), ≥90 to <110 (average, which should
normally  represent 50% of the population), and ≥110 to <120 (high average). Verbal tests
were not complete in one patient with severe hearing loss, who was therefore excluded. A
neuropsychologic test battery for children, (NEPSY), was used290 for evaluating different
qualities such as attention, verbal skills, visuospatial skills, and memory skills. Performance
was evaluated with standard scores on a scale from +1 to -3 (0 – +1 normal, -1, -2 and -3
represent increasing impairment). Records for verbal skills and memory skills were not
complete for 2 and 3 patients, respectively, and these patients were excluded from the
analysis. A neuropsychologist performed cognitive and neuropsychological tests.
School performance was recorded, and the patients were grouped for further
analysis according to whether they attended a special school or class, a normal class
receiving part-time remedial teaching, or a full-time regular class.
The neurodevelopmental data obtained were correlated with the clinical data and
risk factors for neurodevelopmental outcome, collected retrospectively  from the medical
records. Data collected were; gestational age, birth weight, Apgar score, septic infections
with clinical signs and a positive blood culture, seizures, anticonvulsive treatment, use of
aluminum-containing phosphate binders, hypertension, episodes of hypertensive crisis,
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severe hypo/hypervolemia during dialysis, and medical emergencies leading to intensive
care or resuscitation.
Serum aluminum (S-Al) was measured by atomic absorption spectrophotometry.
Exposure to aluminum was estimated as either the mean S-Al concentration based on
several measurements or the peak value. The S-Al level has a strong positive correlation
with the oral dosage of elementary aluminum.187 A value < 0.37 µmol/L was regarded as
normal (1 µmol/L is approximately 27.14 µg/L).
Statistical analysis
Patient survival and GS rates were determined by Kaplan-Meier survival analysis for all 59
patients and 65 grafts. The differences between the survival curves for donors, age groups,
etc. were tested statistically with the log rank test.
Unpaired t tests were used for comparison of continuous parametric data, and the
Mann-Whitney U test for nonparametric comparison between two groups. Analysis of
variance (ANOVA) was used for comparison of more than two groups. Fisher’s Protected
Least Significance Difference (PLSD) was used for post-hoc comparisons. We used paired t
tests or repeated measures ANOVA for testing data for repeated parametric measures and
the Wilcoxon signed rank test for nonparametric data. Pearson´s correlation coefficient was
used for analysis of a linear correlation and multiple regression was used for more than two
independent variables. The Spearman rank correlation coefficient was used for
nonparametric correlations. When nominal data were compared, a contingency table was
used with either Fisher’s exact test or the χ2 (chi-squared) test for more than two groups. A
P value of less than 0.05 was considered significant.
55
RESULTS
PATIENT AND GRAFT SURVIVAL
Patient survival
Patient survival for all patients, 7 years after TX was 98%. One patient (CAD, TX age >2)
died in a hypertensive crisis after developing nephrotic syndrome, leading to graft loss and
dialysis. One patient (LRD, TX age <2 y) with a functioning graft died of a
lymphoproliferative disease 10 years after TX (Table 7).
Table 7. Individual characteristics of patients who lost graftsa
Patient
No.
Diagnosis Age at
TX
Donor
age
Donor Years after
TX
Cause of graft loss
1 NPHS1 1.7 36 LRD 9.8 Death due to LPD with a
functioning graft
2 NPHS1 3.5 15 CAD 2.5 Nephrosis
3 NPHS1 2.6 36 LRD 7.2 HUS
4 NPHS1 1.2 24 CAD 2.3 Nephrosis
4b 5.5 45 CAD 0 Primary non function
4c 8.2 49 CAD 0.3 Nephrosis
5 NPHS1 1.3 36 LRD 1.9 Nephrosis
6 NPHS1 2.7 5 CAD 0.3 Nephrosis, hypertensive
crisis and death
7 NPHS1 1.9 1 CAD 1.5 Nephrosis
8 Prune-Belly 3.8 48 CAD 4.0 Chronic vascular rejection
9 NPHS1 1.1 48 CAD 0 ATN + AR
aAbbreviations used in the table; TX, transplantation; NPHS1, congenital nephrosis with mutations in the
nephrin gene (NPHS1); CAD, cadaver donor; LRD, living related donor; LPD, lymphoproliferative disease;
HUS, hemolytic uremic syndrome; ATN, acute tubular necrosis; AR, acute rejection
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Graft survival
GS for first graft recipients 7 years after TX was 88% for LRD and 80% for CAD recipients
(p = 0.5). GS of the first TX 7 years after TX in the children transplanted when <2 years of
age was 85%, and 81% for the children transplanted between the ages of 2 and 5 years (p =
0.8). Nine grafts were lost, in addition to the two mentioned in the previous section (8
CAD, 3 LRD). The causes of graft loss are summarized in Table 7. One of these patients
lost all her 3 grafts, the others were primary failures. Six grafts were lost owing to
development of nephrotic syndrome in patients transplanted because of NPHS1. No grafts
were lost directly because of technical complications, although these may have contributed
to the primary non-function in one of the patients. GS after 7 years for all TX, including
repeat TX, grouped for both donor source and recipient age are shown in Figure 2. Two out
o f f o ur gr a f t s f r om do no r s un de r t he a g e of si x w e r e l o s t ( p = 0.04 , < 6 v s. > 6 y e a r s ) Ta bl e 7 .
Figure 2. Graft survival up to 7 years after TX in 59 children (65 grafts) <5 years of age at TX
(Kaplan-Meier). No significant difference between survival curves (log-rank test).
>2y TX = between 2–5 years at TX, <2y TX = under 2 years of age at TX, LRD = living
related donor, CAD = cadaver donor, n=number of children at baseline
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Acute rejections (I)
Sixty-seven per cent of our patients suffered at least one and 31% two or more episodes of
AR (range 0-3), during the first 3 months after TX. Late AR episodes were seen in only two
patients. CAD graft recipients had significantly more rejection episodes than LRD graft
recipients (1.3 ± 0.8 vs. 0.6 ± 0.9, p = 0.01). Five episodes (10%) that did not respond to
steroids were treated with anti thymocyte globulin (ATG) or with a monoclonal antibody
(OKT3). Two additional episodes of vascular rejection were treated with plasmapheresis
and cyclophosphamide. All these episodes were reversible and contributed to graft loss in
only one patient. The number of AR (0 vs. 1-3) had no effect on GS.
RENAL FUNCTION (I and II)
Glomerular function and renal plasma flow
 A slow decrease in GFR occurred with time. However, the mean absolute GFR improved
with time (Figure 3).
The GFR was consistently higher in LRD than in CAD recipients, although
significantly so only 1.5 years after TX (85.5 ± 25.0 vs. 67.2 ± 17.1 mL/min/1.73m2, p <
0.05). In both groups, GFR deteriorated with time and was 62.0 ± 16.5 and 45.7 ± 23.9
mL/min/1.73m2 at 7 years for LRD and CAD recipients, respectively. The absolute GFR
improved with time, significantly so for the LRD recipients. The absolute GFR for CAD
recipients was 26.0 ± 7.0 mL/min at 1.5 years and 35.7 ± 12.5 at 7 years after TX. The
absolute GFR in the LRD recipients changed from 30.7 ± 11.8 to 40.4 ± 12.1 (p < 0.05).
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Figure 3. Glomerular filtration rate (GFR) (mean ± sem) for children transplanted <5 years of age,
1.5 to 7 years after transplantation (TX). The upper line (black circles) gives the body
surface area-related GFR (mL/min/1.73m2), the lower line (white circles) gives the GFR in
absolute values (mL/min). The number of children observed at each of four intervals after
TX is given (n). The bars represent median “Chronic allograft damage index” (CADI)
scores, 1.5 to 7 years after TX. */**, p < 0.05 for change of mean values during follow up
(paired t test). Changes in CADI (p = NS, Wilcoxon signed-rank test).
The mean GFR was lower in the children transplanted at <2 years of age than in those
transplanted at >2 years of age (Table 8). The mean absolute GFR remained stable in the
children transplanted at <2 years of age but at a lower level than in the children transplanted
at >2 years of age. The children >2 years of age also improved their absolute GFR with
time (Table 8). The difference was not affected by donor source, since CAD and LRD
recipients were equally distributed (12/14) in the group transplanted at <2 years of age.
Neither donor age, cold ischemia time, HLA-AB-DR mismatch, number of AR,
CsA dose, nor CsA blood trough levels differed between children transplanted at <2 years
of age and children transplanted at >2 years of age. The CsA dose correlated inversely with
the absolute GFR within the group transplanted at <2 years of age at 1.5 years (ρ -0.57, p =
0.03) and within the group transplanted at >2 years of age at 1.5 and 3 years (ρ = -0.67, p =
0.01 and ρ  = -0.64, p = 0.02, respectively). However, the groups did not show any
significant differences with respect to possible markers of CsA toxicity, such as
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hyperkalemia or hyperuricemia. No correlations between absolute GFR and donor age, cold
ischemia time, HLA mismatch, or number of AR were found within the age groups.
The absolute RPF differed between the age groups at 1.5 years, and improved
significantly in the older age group (Table 8).
Except in two patients suffering from nephrotic syndrome at the control visit,
proteinuria was mild and transient (270-440 mg/m2/24h) and was seen in only two patients
at 18 months, 3, and 5 years and in one patient 7 years after TX.
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Hypertension
Of 43 patients, 33 (77%) were without antihypertensive medication 18 months after TX.
The corresponding figures 3, 5, and 7 years after TX were 28/31 (90%), 22/23 (96%) and
11/12 (92%), respectively. The mean blood pressure after 18 months was similar for the
LRD and CAD recipients, 114/63 (SD 11/8) and 114/63 (SD 12/14), respectively. Seven
years after TX, the corresponding mean values were 122/68 (14/15) for LRD and 126/67
(11/11) for CAD recipients (p = NS). Only four patients used loop-acting diuretics at 18
months, but not subsequently.
Tubular function and handling of electrolytes
Hyperuricemia occurred in 43-67% of the patients, abnormal handling of potassium was
seen in 17-33%, and most patients had a subnormal concentrating capacity during follow-
up (Figure 4). The mean values for serum potassium, serum urate, and Clurate did not differ
significantly between those with CAD and those with LRD grafts. Serum urate
concentration showed an inverse correlation with Clurate at every follow-up (r = -0.40, p =
0.04; r = -0.51, p = 0.01; r = -0.49, p = 0.02; r = -0.70, p = 0.01, at 1.5, 3, 5, and 7 years
after TX, respectively). Serum urate concentration also showed an inverse correlation with
ClLi 1.5 (r = -0.43, p = 0.01) and 3 (r = -0.46, p = 0.01) years after TX, respectively. Serum
urate correlated inversely with GFR (r = -0.47, p = 0.009; r = -0.59, p < 0.001; r = -0.67,
p = 0.02) at every follow-up, except at 5 years. Serum urate did not correlate with CsA
dose, CsA blood levels, RPF or FPR.
Patients with hyperkalemia had significantly a lower GFR at 3 years than
normokalemic patients (47.7 ± 17.8 vs. 80.0 ± 19.1 mL/min/1.73m2, p < 0.001). The CsA
doses and trough levels were higher in the hyperkalemic patients, but these differences did
not reach statistical significance at 3 years. The patients who were hyperkalemic 1.5 years
after TX were given higher CsA doses (10.8 ± 6.1 vs. 7.8 ± 2.0 mg/kg, p = 0.02). The
proportion of patients with hyperkalemia in combination with a TTKG < 6.0 is shown in
Figure 4. Only one of these patients had suppressed adrenal function. Three years after TX,
this patient had an extremely low TTKG value of 2.0.
In most patients, concentrating capacity was low (Figure 4) and the mean values
were consistently lower in the CAD than in the LRD patients.
FeNa and FPR remained stable with time, regardless of donor source, and showed
no correlation with CsA dose or CsA trough blood levels 1.5, 3, 5, or 7 years after TX.
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Figure 4. The proportions of patients with pathological potassium handling (S-K >5.3 mmol/L or use
of potassium binding resins, TTKG <6.0, hyperuricemia (S-urate >330 µmol/L), and
reduced urinary concentrating capacity (U-osmol <750 mosm/kg).
RENAL HISTOPATHOLOGY (II)
Overall histology and lost grafts
Two patients with NPHS1 who lost their grafts after developing nephrosis, had a protocol
biopsy taken at 1.5 years. One of them (no. 5, Table 7). had a grade II chronic allograft
nephropathy with an overlying grade I AR. The other patient’s biopsy was regarded as
normal (no. 4, Table 7). One patient (no. 9) lost her graft early after TX on account of AR
combined with ATN. Another patient (no. 3) had glomerular necrosis and arterial
thrombosis, in addition to grade II chronic allograft nephropathy, in his protocol biopsy at 7
years, because of a hemolytic uremic syndrome at the time of the biopsy. This patient
subsequently lost his graft. In addition, one patient (no. 1) with a functioning graft died
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from a lymphoproliferative disease almost 10 years after TX. This patient had a biopsy
regarded as normal at 7 years.
The histological changes were mostly scored as mild or very mild, and most
biopsies were regarded as normal according to the BC (Table 9). The percentage of
biopsies with chronic allograft nephropathy remained stable.
Table 9. Distribution of chronic allograft nephropathy according to the Banff classification
in 51 children transplanted when under 5 years of age
Years after TX Normal Grade I Grade II Grade III Total
n (%) n (%) n (%) n (%) n
1.5 20 (69%) 6 (21%) 2 (7%) 1 (3%) 29
3 17 (57%) 7 (23%) 6 (20%) – 30
5 13 (52%) 7 (28%) 5 (20%) – 25
7 9 (69%) 2 (15%) 2 (15%) – 13
Grade I = mild, Grade II = moderate, Grade III = severe chronic transplant nephropathy
The median CADI score for all patients was 2.5 (score 0-36) at 1.5 years and 4.0, 4.0, and
3.5, at 3, 5, and 7 years after TX, respectively (Figure 3). Thus, as a whole, the
histopathologic findings did not show signs of deterioration. The incidences of the most
frequent individual histopathologic findings and their corresponding mean scores are
presented in Table 10. Interstitial inflammation with focal lymphocytes tended to decrease
with time, while the incidence of mild diffuse fibrosis tended to increase with time. A major
finding was the increase in global glomerular sclerosis. The proportion of totally sclerotic
glomeruli increased markedly with time. At 1.5 years, the mean PSG was only 3%, but at 5
years after TX it had increased to 36% (p = 0.0008). The glomerular sclerosis was not
reflected in graft function. The most frequent vascular findings were arterial and arteriolar
intimal proliferation, encountered in 20% and 24% of the patients at 5 and in 46% and 15%
at 7 years, respectively. The most prominent tubular finding was epithelial atrophy in 76%
of the patients at 1.5 years and in 54% at 7 years. Tubular casts were found in
approximately half of the biopsies. They were almost exclusively hyaline. However, the
mean and median scores were low, indicating that the changes encountered were mild.
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Table 10. Incidence of the most common histopathologic findings (%) and corresponding mean scores
(range 0-6), 1.5 to 7 years after transplantation in 51 patients who received transplants
before the age of 5 years.
Years after transplantation 1.5 3 5 7
Number of biopsies 29 30 25 13
% mean
score
% mean
score
% mean
score
% mean
score
Interstitium
Focal lymphocytes 72 1.2 50 1.0 60 1.2 31 0.5
Diffuse lymphocytes 28 0.5 27 0.7 32 0.7 23 0.6
Focal fibrosis 62 1.1 63 1.1 52 1.2 15 0.2
Diffuse fibrosis 28 0.9 40 1.1 36 1.2 46 1.4
Glomeruli
Global mesangial cell
proliferation
34 0.5 23 0.4 16 0.2 15 0.2
Global mesangial
matrix increase
72 1.3 73 1.4 60 1.0 46 0.8
Global Bowman
capsular thickening
52 0.9 43 0.8 28 0.5 23 0.2
Percentage of sclerotic
glomeruli
3 19 36 33
Vessels
Arterial intimal
proliferation
17 0.5 30 0.8 20 0.5 46 1.2
Arteriolar intimal
proliferation
14 0.3 17 0.4 24 0.6 15 0.2
Tubuli
Epithelial atrophy 76 1.6 70 1.6 48 1.4 54 1.2
Casts 48 0.7 43 0.8 44 0.8 69 0.9
Lymphocytes 14 0.3 17 0.2 12 0.1 8 0.1
Dilatation 24 0.4 30 0.5 26 0.5 54 1.1
Basement membrane
thickening
34 0.8 33 0.5 8 0.2 15 0.2
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Acute rejection and cyclosporine toxicity
The biopsies were protocol biopsies taken in clinically stable situations years after TX.
Findings of AR and CsA toxicity were thus seldom seen. One of the patients had a
clinically and FNAB documented late AR at the time of protocol core biopsy. This AR
episode was partially treated at the time of biopsy and showed only mild tubulitis (i.e. <4
mononuclear cells / tubular cross section). The rejection could be reversed with steroids.
Borderline changes (i.e. very mild AR) were additionally found in two patients without
clinical signs of AR.
The number of early AR influenced the CADI. Patients with one or more rejection
episodes had a higher mean CADI at every follow-up than those without rejection episodes
(5.2 ± 6.1 vs. 3.0 ± 2.6, at 1.5 years, 6.8 ± 5.1 vs. 4.3 ± 3.9, at 3 years, 8.9 ± 5.5 vs. 3.5 ±
3.1, at 5 years and 6.7 ± 6.6 vs. 5.2 ± 4.6 at 7 years). The difference in CADI was not
statistically significant at 1.5 and 3 years. The increase in the mean CADI (∆CADI)
between 1.5 and 3 years was similar in the two groups (2.2 ± 7.1 vs. 2.3 ± 6.8). However,
∆CADI was 4.8 ± 8.2 in the group with one or more rejection episodes between 1.5 and 5
years in contrast to a ∆CADI of 0.9 ± 5.6 in the group without rejection episodes. At 5
years, the difference in CADI was significant between the groups (3.5 ± 3.1 vs. 8.9 ± 5.5, p
= 0.001). A correlation between the number of early AR episodes and the CADI at 5 years
was also shown with the Spearman test (ρ = 0.67, p = 0.001).
When patients were divided according to HLA mismatch (0-1 in the AB loci and 0
in the DR loci vs. all others), cold ischemia time (<24 vs. >24 hours for CAD recipients), or
donor age (<40 vs. >40 years), this did not affect the CADI.
Histopathologic findings assumed to be related to CsA toxicity were rarely
encountered. Isometric vacuolization was seen in three patients (in one patient each at 1.5, 3
and 7 years). Their mean CsA doses were moderate, from 2.9 to 6.7 mg/kg. Nodular
hyaline deposits were seen in the afferent arterioles in 6 patients (in 2 at 1.5 and at 7 years
and in one patient each at 3 and at 5 years, respectively). Except for one patient with a CsA
dose of 10.0 mg/kg, their doses were moderate, ranging from 5.3 to 6.7 mg/kg. Except in
one case, the hyaline deposits and vacuolizations appeared in different patients. CsA doses
or blood levels did not correlate with any of the histological parameters evaluated.
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Renal function and histology
The body surface area related mean GFR deteriorated slowly with time, although the CADI
remained stable and low. In contrast, we recorded an improvement in the absolute GFR
with time (Figure 3). Patients classified, according to the BC, as having a normal biopsy,
had a better mean GFR (74.6 ± 19.2) 3 years after TX than the group of patients with some
degree of chronic allograft nephropathy (59.4 ± 18.0) (p = 0.04). Patients with grade II
allograft nephropathy had a mean GFR below 60 mL/min/1.73m2 at every follow up. The
CADI index also correlated inversely with graft function (ρ  = -0.44, p = 0.02 and ρ =
-0.46, p = 0.03, at 3 and 5 years, respectively). However, the individual histological
scorings (e.g. diffuse fibrosis) did not correlate with graft function.
The CADI score at 3 years correlated inversely with later function at 5 years after
TX (ρ = -0.58, p = 0.01). The patients with a higher than median CADI score (i.e.> 4.5) at 3
years had a lower GFR at 5 years than those with a lower CADI score (50.6 ± 17.4 vs. 70.4
± 18.6, respectively, p = 0.03).
Donor source and histology
CAD recipients suffered more AR and showed more pathological findings in the biopsies
than did LRD recipients. However, the differences were slight and the median CADI was
significantly higher in the CAD recipients only at 3 and 5 years (5.8 vs. 3.3 and 6.3 vs. 3.0,
respectively, p < 0.05). The changes in CADI with time for the CAD recipients were not
statistically significant; thus the median CADI remained stable with time for both the CAD
and the LRD recipients. The CsA doses of the two groups were closely similar.
 Recipient age and histology
No significant difference in the CADI score was found between patients receiving their
graft <2 years of age and patients >2 years of age at TX (Table 8). The CADI also
remained stable with time in both groups. Individual histopathologic changes did not differ
between the groups, except for the incidence of totally sclerotic glomeruli, which increased
in both groups with time, but at a different pace. PSG was 3% for both groups at 1.5 years,
21% for recipients <2 years vs. 16% for recipients >2 years at 3 years and 41% vs. 32%,
respectively at 5 years (all p = NS). After 7 years, 45% (SD 14) of the glomeruli had
collapsed in the group transplanted at <2 years of age as compared with 24% (SD 15) in the
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group transplanted at >2 years of age (p = 0.04). There were no differences in the mean
number of AR, and the CsA doses were also evenly distributed between the groups.
Growth hormone and histology
 Two patients receiving GH lost their grafts (one on account of nephrosis, the other after
developing a hemolytic uremic syndrome). No late AR occurred in the GH treatment group.
The groups did not differ with respect to the number of early AR (1.3 ± 1.1 vs. 0.9 ± 0.8,
respectively, p = 0.9). GFR did not differ significantly between the groups. The mean
CADI was slightly higher in the group receiving GH at 3 (8.3 ± 5.7 vs. 5.1 ± 4.3) and 5
years (9.6 ± 5.4 vs. 5.6 ± 5.0), but the difference was not statistically significant.
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GROWTH (III)
Growth without growth hormone therapy
Catch-up growth was seen in 81% of our children who did not receive GH treatment at any
time. Their mean hSDS had changed from -1.4 ± 0.9 at TX to -0.8 ± 0.7 at 7 years after TX
(p < 0.0001) (Figure 5). The corresponding figures were -1.6 ± 0.9 and -0.8 ± 0.7 (p <
0.0001) for the 17 children who had been observed throughout the entire period of 7 years.
Figure 5. Mean hSDS and 95% confidence intervals (shaded areas) up to 7 years after TX for 30
children without the use of growth hormone therapy (upper line), and for 11 children
receiving recombinant human growth hormone (GH) after TX (lower line), transplanted
when <5 years of age. For both groups, p < 0.0001 for improvement of hSDS during follow-
up (ANOVA). Arrow = median start of GH treatment
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Recipients <2 years of age showed slight catch-up growth during the first years after TX (p
= NS), but subsequently a slight deceleration (Table 8). The 9 patients <2 years of age at
TX, who had been observed for the entire period of 7 years, had a hSDS of -1.2 ± 0.9 at TX
and -1.1 ± 0.5 at 7 years (p = NS). Recipients >2 years showed some catch-up growth
throughout the follow-up (Table 8). The 8 children >2 years of age at TX, who had been
observed for the entire period of 7 years, improved their hSDS from -2.0 ± 0.9 to -0.4 ± 0.8
at 7 years (p < 0.0001). Thus, age at TX was positively correlated with height increment
after TX (∆hSDS from TX to 7 years after TX) (r = 0.58, p = 0.02). Recipients <2 years of
age had a higher mean hSDS than did recipients >2 years of age at the time of TX. Thus,
hSDS at TX was inversely correlated with later height increment (r = -0.80, p = 0.0002).
However, when both variables (age and hSDS at TX) were used in a multiple regression
model, only hSDS at TX showed a significant correlation with ∆hSDS, from TX to 7 years
after TX (p = 0.002).
The GFR at 5 years showed a positive linear correlation with the subsequent growth
rate from 5 to 7 years after TX (r = 0.58, p = 0.01). The GFR at 1.5 and 3 years did not
show a correlation with the subsequent growth rate.
Catch-up growth between 5 and 7 years after TX was seen in only 35% of the
children without GH treatment. The mean GFR at 5 years was 80.8 ± 13.6 mL/min/1.73m2
in the group with catch-up growth vs. 61.8 ± 16.2 in the group without catch-up growth (p
= 0.03).
Growth hormone therapy
Thirty (73%) children did not receive GH treatment at any time. GH therapy was given to
11 (27%) patients after TX. There were significantly more boys in the group receiving GH
(10/11 vs. 15/30 in the non-treatment group, p = 0.03). The groups did not differ in disease,
donor source, age at TX, age at initiation of dialysis treatment, or time on dialysis. GS 7
years after TX was 80% for patients receiving GH and 81% for patients without GH
treatment (p = NS).
In all the children receiving GH, catch-up growth was seen after initiation of
treatment. Their mean hSDS at TX was -2.5 ± 0.9, and, 7 years after TX it was -1.1 ± 0.9 (p
< 0.0001) (Figure 5).
The patients in the GH treatment group did not have any late AR and did not receive
significantly higher doses of MP than the untreated group on leaving hospital after TX
(0.40 ± 0.12 mg/kg/day vs. 0.38 ± 0.12, p = NS). Both groups also had similar mean GFR
on leaving hospital, but at follow-up, the GH treatment group showed a tendency to a lower
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mean GFR than the untreated group (47.2 ± 11.4 mL/min/1.73m2 vs. 58.6 ± 18.2, at 7
years, p = 0.09).
Bone age
The hBA showed no significant differences during follow-up or between the two age
groups (<2 vs. 2–5 years at TX) without GH. The hBA at TX showed a strong inverse
correlation with ∆hBA from TX to 7 years (r = -0.90, p = 0.001). Age at TX was not
correlated with the change in ∆hBA.
GH treatment did not significantly affect bone maturation. In the children receiving
GH therapy, the mean BA changed only 5.5 ± 1.1 years during 6 years after TX.
Weight
The mean W/H was -4.9 ± 9.5% for the group without GH at TX, and had changed
significantly with time to 8.8 ± 20.2% after 7 years (p < 0.0001). The change was seen
particularly in the children <2 years of age at TX, whose mean W/H changed  from -6.2 ±
9.1 at baseline to 17.3 ± 24.4 at 7 years.
The mean W/H for the GH treatment group also changed significantly with time
from -4.5 ± 9.9% at TX to 7.5 ± 6.9% at 7 years (p < 0.0001).
NEURODEVELOPMENTAL OUTCOME (IV-V)
Major neurodevelopmental sequelae and neuroradiology
Of the 33 children of school age who were included in the neurodevelopmental studies, 25
(76%) had a motor performance within normal limits.
Three patients had hemiplegia. One had bilateral infarcts in the areas supplied by
the posterior cerebral artery in addition to grade 3 border-zone infarcts. One had a large
middle cerebral artery infarct and an anterior inferior cerebellar artery infarct, which were
sequelae of a cannulation complication during nephrosis in a hypercoagulable state. One of
them had several small infarct-like lesions bilaterally in the basal ganglia in addition to
grade 2 border-zone infarcts.
One small infarct in the head of the caudate nucleus was recorded in one patient.
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One patient had minor motor difficulties as a result of mild cerebral palsy in addition to an
inferior IQ level. This patient had an episode of severe hypovolemia during dialysis and
mild bilateral infarctions were documented in the watershed areas.
One patient had severe impairment of vision due to bilateral eye hamartoma, and
thus had difficulties in some co-ordination tasks. In addition, one patient, later diagnosed as
having Asperger syndrome, had behavioral difficulties.
One patient with a functioning graft died of a lymphoproliferative disease 10 years
after TX. She had a watershed ischemic finding scored as mild (grade 1), but otherwise
normal motor performance at school age.
A typical finding, seen in 18 patients, was the occurrence of chronic infarct-like
lesions in the periventricular white matter and centrum semiovale. The location of the
lesions corresponded to the internal junctional zones between the deep and superficial
territories of the middle cerebral artery. Cortical extension of these lesions, if present, was
typically seen in the watershed regions between the main arterial territories.
Ten patients had grade 1 lesions, with only a few small punctate foci confined to the
deep white matter. Four patients with only one lesion were included in this group. Six
patients had grade 2 lesions, which were larger and confluent or more numerous than those
of grade 1, and had subtle cortical extensions to the posterior watershed region. Two
patients had extensive cortical-subcortical border-zone infarcts with marked focal
parenchymal loss, affecting both the anterior and posterior watershed regions and scored as
grade 3.
In six patients, bilateral T2 hyperintensities were seen in the cerebellar hemispheric
white matter. One of these had grade 3 border-zone infarcts, four grade 2, and one grade 1.
Cerebellar atrophy was not seen and the brain stem was normal in all the patients.
Of the 4 patients with diagnoses other than NPHS1, one had grade 2 and two had
grade 1 watershed infarcts.
Two patients had moderate central atrophy. Only mild cortical atrophy was
observed, and it was seen in the frontal and parietal lobes of three patients. No temporal or
occipital atrophy was encountered.
Occasional findings included nodular periventricular heterotopias in two patients
(one with NPHS1 and the other with prune-belly syndrome), bilateral hippocampal atrophy
in a patient with grade 1 internal junctional lesions, and bilateral T1 hyperintensities in the
globus pallidus in one. The two patients who had two MRI studies showed no  change in
the findings during the interval. Nor was there any difference between the findings in the
1T or the 1.5 T units. In 13 patients they were entirely normal. The MRI findings are
summarized in Table 11.
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Table 11. Brain MRI findings in 33 school-aged children
after renal transplantation at <5 years of agea
Findings Number of
patients
%
Border zone infarcts 18 54
Grade 1 10 30
Grade 2 6 18
Grade 3 2 6
Cerebellar lesions 6 18
Large vessel infarcts 2 6
Atrophy 5 15
Cortical 3 9
Central 2 6
Other 4 12
Normal 13 40
aSome of the patients had more than one finding;
thus the sum of the percentages is not 100%
The pre-TX CT studies were performed either as presurgical screening or at the time of a
clinical crisis. In both the patients with grade 3 watershed infarcts, the vascular lesions were
visible before TX. One of them also had bilateral chronic posterior cerebral artery infarcts,
already visible in the first CT images. One patient was studied during a hypertensive crisis
with encephalopathy and seizures and, at that time, had hypodense edematous lesions in the
watershed areas; later on, his MRI showed grade 2 infarcts. Three patients showed marked
widening of the cortical and central cerebrospinal fluid spaces, which was no longer visible
in post-TX MRI. Three of the remaining border-zone lesions were seen in CT, one patient
had unilateral lesions in CT but bilateral infarcts in MRI. The small caudate head infarct
was also visible in CT images.
Factors significantly correlating factors with the border-zone lesions were dialysis
time and hemodynamic crises. Eleven of the 18 with border-zone lesions had some history
of hemodynamic crises compared to only three (out of 15) in the group without border-zone
lesions (p = 0.03). All the patients with grade 2 or 3 infarcts had histories of significant
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clinical crises. There were six children with hypertensive crises; four of them had
hypovolemic states requiring cardiorespiratory resuscitation, the remaining four having less
severe but significant hypovolemic episodes. Time spent on dialysis was 1.7 ± 1.4 vs. 0.8 ±
0.3 years (p = 0.02) (V).
EEG and anticonvulsive treatment
Eleven children (35%) had an abnormal EEG recording after TX; however, only 5 patients
(15%) were on anticonvulsive medication after TX (4 of them in the special education
group). All of them had ischemic lesions on MRI. Termination of treatment was planned in
2 of these patients. One of them had had no seizures after TX and the other had a normal
EEG recording. The patients with abnormal EEG, but without medication, had no seizures
documented after TX. A focal- or a paroxysmal abnormality was seen in 2 of these patients.
Three patients had both focal- and paroxysmal abnormalities (IV).
Audiometry
All except 2 patients (7%) had normal hearing. These 2 patients (twins) had moderate
SNHL of unknown origin affecting both the middle and the high frequencies, and were
using hearing aids and attending a special class. Bilateral mild to moderate high frequency
(6 to 8 kHz) hearing impairment was recorded in 4 additional patients. One of them had
received several potentially ototoxic drugs as treatment for his neuroblastoma. The other 3
children had also had several episodes of septic infections treated with potentially ototoxic
antibiotics (IV).
Cognitive performance
The mean verbal IQ was 87.5 ± 13.4 (range 65.0–108.0) and the non-verbal IQ was 87.5 ±
14.9 (range 55.0–118.0). Three patients (9%) were regarded as mentally deficient. Fourteen
patients (42%) were classified as borderline to low average. An average performance was
seen in 14 children (42%). The non-verbal performance was slightly better in 2 children
classified as high average (114.0 and 118.0, respectively). The mean IQ level of the patients
with normal school performance was within the normal range (i.e. >90) (Table 12).
The mean scores in the neuropsychological tests were -0.2 ± 0.4 for attention and
verbal skills, -0.4 ± 0.5 for memory skills and -0.5 ± 0.5 for visuospatial skills. Eight
patients (24%) had reduced attention spans (score -1.0 or less). The corresponding numbers
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of patients who scored -1.0 or less for verbal, visuospatial, and memory skills were 2 (6%),
8 (24%) and 6 (20%), respectively. Difficulties in neuropsychological tests were mostly
seen in children with known motor problems and/or inferior school performance (IV).
Table 12. Neurodevelopmental outcome and risk factors after renal transplantation in early
childhood in 33 school-aged children, grouped according to school performance.a
Special education
n = 7
Remedial teaching
n = 6
Normal class
n = 20
pe
Neurodevelopmental scoreb 17.4 ± 9.2 5.0 ± 3.4 6.9 ± 4.5 0.0004
Verbal IQc 72.8 ± 8.1 86.0 ± 11.5 92.3 ± 12.1 0.001
Hemiplegia, n (%) 3 (43) 0 0 0.002
Watershed infarcts, n (%) 5 (71) 5 (83) 8 (40) 0.1
Age at TX (years) 2.4 ± 0.8 3.1 ± 1.4 2.2 ± 1.0 0.2
Dialysis time (years) 2.2 ± 1.6 1.1 ± 1.0 1.0 ± 0.9 0.05
Gestational age (weeks) 34.6 ± 2.4 37.8 ± 0.8 36.8 ± 1.8 0.01
Hypertensive crisesd 0.9 ± 0.9 0.2 ± 0.4 0.05 ± 0.2 0.002
aPatients are grouped according to their enrollment either in special education classes/schools, in regular
classes with remedial assistance, or in normal classes. n = number of patients in each group.
bMean score ± standard deviation. The worst possible score is 44.287 (IV)
cIntelligence quotient levels using the Wechsler intelligence scale, revised.289
dMean number of events (± standard deviation) per patient.
eNo significant differences between the remedial/normal class groups (Fisher´s PLSD).
School performance
Twenty-six (79%) of the children attended normal schools. Six of them had remedial
teaching because of dyscalculia, dysgraphia, or both. Seven children (21%) attended a
special school, 2 of them, however, solely on account of their hearing handicap. In this
group, cognitive performance and outcome were inferior. However, no significant
differences were seen between those attending a normal class and those attending a normal
class with remedial assistance (IV) (Table 12).
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Risk factors and events
Neonatal
Most of the children had been born prematurely, at a mean gestational age of 36.5 ± 2.1
weeks, with a mean birth weight of 2.7 ± 0.6 kg. Half of the pregnancies and deliveries had
complications, the most frequent of which was aspiration of meconium, which occurred in
4 patients. Toxemia, maternal infection, pneumothorax, imminent asphyxia, and breech
presentation were recorded in 3 cases each. The children in the special education group
were born more prematurely than those receiving remedial teaching and those in the normal
class (Table 12). However, only 1 child in the group receiving special education had any of
the aforementioned  complications related to pregnancy or delivery. The special education
group also had similar mean Apgar scores, and the need for artificial ventilation was the
same in all groups (IV).
Septic infections
Most septic infections (97 of 112; 87%) occurred before dialysis. Only 7 and 8 episodes
were documented during dialysis and after TX, respectively. The children with educational
problems did not have a history of a greater number of septic infections before dialysis,
during dialysis, or after TX (IV).
Hypertension
Hypertension was documented in 27 (82%) of the children before and during dialysis. This
prevalence was dramatically reduced after TX, being only 24% 18 months post-TX. Eight
episodes of hypertensive crises had occurred in 6 patients, all but 1 episode during dialysis
therapy. The patients in the special education group had had significantly more
hypertensive crises than the children in the normal class (Table 12).
Seizures
Seventeen (52%) patients had a history of convulsions. The majority of seizures had
occurred during dialysis and after TX. Seizures were documented in 12 patients during
dialysis. Five of these patients had received anticonvulsive treatment and continued to
receive medication even after TX. Five of the 7 patients without medication had a defined
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etiology (i.e. hyponatremia, hypocalcemia, transient cerebral ischemia); none of them
continued to have seizures after TX. Eight children (24%) had seizures after TX; 4 of them
had only a single episode (with a documented etiology, i.e. head trauma, febrile convulsion,
or hyponatremia), and none of them had any seizures prior to TX or received medication
after TX. Eighty-three percent of all seizures after TX occurred in only 3 patients. The
patients receiving special education had had more seizures than those in the normal class
5.9 ± 8.6 vs. 0.7 ± 0.9, p = 0.03) (IV).
Aluminum toxicity
Sixteen (48%) of the patients had been using aluminum-containing phosphate binders for a
mean period of 9.7 ± 7.8 months. The patients receiving aluminum orally had a
significantly higher mean S-Al (1.02 ± 0.75 vs. 0.47 ± 0.32, p = 0.03), but not a
significantly higher peak value (2.81 ± 2.61 vs. 1.26 ± 1.97, p = NS). Only two of the
patients receiving special education had received aluminum orally, one of whom only for
one month. The highest mean S-Al values were recorded in the patients with normal school
performance, although the difference was not significant. All the patients with S-Al higher
than the mean (1.02 µmol/L) had normal school performance (IV).
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DISCUSSION
PATIENT AND GRAFT SURVIVAL
The overall patient survival and GS rates presented in this thesis are better than those
reported in multicenter registry reports (Table 1).38 Our results in small children and infants
receiving kidneys from LRD are comparable with the best results in single center reports
(Table 1). However, some centers have reported a 100% 5-year GS in LRD recipients <5
years of age.44 However, the most important finding in this thesis is that regardless of age,
children receiving a CAD graft show GS rates comparable with those of LRD recipients.
For children between the ages of 2 and 5 years at TX, GS at 7 years after TX was 78% for
CAD and 80 % for LRD recipients (Figure 2). The corresponding figures for recipients <2
years, were 75% and 92% for CAD and LRD recipients, respectively (p = NS) (Figure 2).
These figures are better than those reported earlier, with the exception of the report by
Cochat et al.45 We have been using triple immunosuppression in all our patients. Many
centers have used sequential therapy,40 but the results summarized in Table 1 have mainly
originated during the CsA era. Some of the centers have converted to tacrolimus as the
main immunosuppressant.53 In the literature, there are very few reports on long-term results
with tacrolimus in children, but they seem to be comparable with those achieved with CsA
as the main immunosuppressant. Some authors underline the importance of using only LRD
kidneys in infants and small children.40 However, in the light of our own experience, adult
CAD grafts can be used successfully, regardless of recipient age.
Graft loss due to vascular thrombosis is reported in 12% of TX in the NAPRTCS
registry report.38 The incidence of graft thrombosis is even higher in small children. In the
UNOS report covering pediatric LRD recipients, graft thrombosis was responsible for
23.8% of graft losses in children <2 years of age as compared to only 5.9% in children
6–12 years of age.51 We did not have a single case of vascular thrombosis after TX and this
is probably one explanation for the good GS in our study. ATN is again one of the major
risk factors for graft thrombosis in both LRD and CAD recipients.17 Superior GS rates have
been reported in infants and small children without ATN.53 ATN in combination with AR
contributed to graft loss in only one of our patients. Surgical technique and experience,
perioperative management, etc, may have a major impact on vascular and immediate post-
operative complications, but these factors are difficult to assess.63
One m ust a lso r e m e mbe r t ha t t he m a jor i ty, or six gr a f t s, wer e lost on ac c ount of 
r e cur r enc e of ne phr ot i c syndr ome a f t e r T X in pat i e nt s wi t h NPHS1 ( Tabl e 7) ,71 a nd not bec a use 
of CR or AR, whi c h a r e t he ot her pr i nc ipa l c a use s of gr a f t l oss r e por t ed i n t he l i te r a tur e .38
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The finding that low donor age is a major risk factor for GS changed the policy of the
UNOS of offering mainly pediatric kidneys to pediatric patients.11 The chief complication
associated with young donor age is graft thrombosis.17 Low donor age was also a risk factor
for graft loss in our patients, but interestingly, not because of graft thrombosis. However,
the relatively small number of patients in our study hampers the interpretation of risk
factors. Thus, we have to be cautious about drawing definitive conclusions concerning their
importance.
We have documented more AR than are usually reported for children.38 One
explanation could be a higher immune reactivity in small children, suggested by some
authors,163 but another is our protocol of using FNAB two to three times weekly after TX to
detect AR.164 With this protocol, even before there are major clinical signs, early
immunoactivation can be documented and treated. The fact that only one graft was lost as a
result of an AR is compatible with the latter explanation.
RENAL FUNCTION (I)
A slow decrease in GFR occurred with time, which seems to be inevitable after TX. In the
1995 NAPRTCS report, the mean calculated creatinine clearance 5 years after TX for
children 2-5 years of age at TX was approximately 65 mL/min/1.73m2. From a level close
to 100 mL/min/1.73m2, 6 months after TX, the decline was remarkable.85
Reports in which the GFR has been measured are few and some of them are
summarized in Table 3. The GFR ranged from 40-70 mL/min/1.73m2, 4-6 years after TX.
However, the majority of patients in Table 3 were far older than those reported in this
study. There are only occasional reports in the literature where the long-term GFR has been
measured in small children. Compared with previous reports, our results are quite
satisfactory, with a mean GFR of 64 and 70 mL/min/1.73m2 for CAD and LRD recipients
respectively, 5 years after TX.
The mean absolute GFR in our patients remained stable (Figure 3). A stable
absolute GFR combined with a decrease with time in body surface-corrected GFR, has been
reported previously.54,83 The absolute GFR also remained stable in the patients <2 years of
age at TX, but at a significantly lower level than in patients transplanted at >2 years of age.
In addition, the younger patients only maintained their absolute GFR during follow-up, in
contrast to the older patients, in whom we documented a slight improvement in GFR with
time (Table 8).
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The analyses of different risk factors did not afford a clear explanation for this difference
between the age groups. It was not affected by donor source. The number of patients in the
study was unfortunately too small to allow further stratifying of the data according to both
age and recipient group. However, the majority of the patients in the group transplanted at
<2 years of age were LRD recipients (73%), who had slightly better function than CAD
recipients. The numbers of AR and of CsA dosing were also equally distributed between
the groups (Table 8). The CADI was similar between the groups and, thus, the difference
was not explained by chronic allograft nephropathy (see later section on renal
histopathology).
The adult kidney seems to adjust its function to the body size and needs of the
smaller recipient.125 However, as the child grows, the compensatory increase in graft
function becomes inadequate, and results in a decline in the surface-corrected GFR. This
seemed to be crucial, particularly for the youngest children, in whom improvement in the
absolute GFR is required to maintain a stable corrected GFR.
Our long-term measurements of RPF were comparable (regardless of donor source)
to those previously reported, approximately 250–300 mL/min/1.73m2.82,87 In very small
children, however, renal blood flow into the adult kidney may also be reduced leading to
ischemia and reduced function. We did not study the process of functional adaptation
immediately after TX. RPF was lower in the younger children, but not significantly so.
However, corrected RPF diminished with time significantly in the younger age group, in
contrast to the older age group. Salvatierra et al.,127 have shown that infants receiving an
ASK increase their aortic blood flow immediately after TX, in order to perfuse the ASK.
Renal artery blood flow was still suboptimal as compared with the pre-nephrectomized
values in the donor. After 4-6 months the renal artery blood flow continued to decrease
despite continued maintenance of the optimum intravascular volume.127 With more
aggressive optimization of the intravascular volume by nasogastric or gastrostomy tube
feeding in infants receiving ASK, the same authors showed an improved GFR at 1 year of
102 ± 10 compared with 66 ± 3 mL/min/1.73m2 of controls prior to the protocol.128 It is
tempting, however, to speculate that the discrepancy between the perfusion capacity of
small children and the need of an adult-sized kidney also leads to a greater extent of
irreversible long-term loss of function by the transplanted kidney as compared with older
children.
The majority of our patients were already without antihypertensive medication 1.5
years after TX. In the registry report of NAPRTCS, antihypertensive medication was still
being used by 58% at 5 years,69 compared to our figure of only 4%. This difference is
probably a reflection of the good graft function maintained in the majority of our patients.
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In addition, mean blood pressure measurements were not higher in the CAD recipients, in
whom hypertension is more frequent than in LRD recipients.96 The diminishing incidence
of hypertension with time, which has been shown by others as well as ourselves,44,69,88
probably reflects the tapering of the CsA doses with time.20,94
CsA probably influences sodium handling and proximal tubular resorption.105-107
FPR was higher in CAD than in LRD recipients at 1.5 years after TX, but FeNa and FPR
remained stable with time in both recipient groups. In TX recipients with stable graft
function, the impact of CsA is presumably moderate.108
Hyperkalemia is a more frequent side effect in renal transplant recipients receiving
CsA treatment.23 In our patients, 17-21% had hyperkalemia and a TTKG < 6.0 (Figure 4).
Hyperkalemia did not consistently correlate with GFR and the patients with hyperkalemia
did not always have a significantly reduced GFR. The combination of hyperkalemia and a
lowered TTKG indicates reduced ability of the distal nephron to secrete potassium.111 Only
one patient had suppressed adrenal function, so the decreased potassium secretion probably
reflects a direct tubulotoxic effect of CsA,112,113 involving calcineurin.114
Seven years after TX hyperuricemia was documented in over 50% of our patients.
This contrasts with one report in which the incidence decreased with time during 30
months.119 The authors attributed their finding to the diminishing use of diuretics and the
tapering of CsA with time. In our patients, the degree of hyperuricemia was not influenced
by the use of diuretics, since no patient was receiving diuretics 3, 5, or 7 years after TX.
However, our patients had higher doses of CsA and CsA blood levels than those reported
by Edvardsson et al.119 The mechanisms underlying hyperuricemia in CsA-treated patients
are not fully understood. Some authors see hyperuricemia solely as a GFR-related
effect.108,118 Other reports suggest an independent tubular effect of CsA, leading to a defect
in the proximal tubular handling of uric acid.24,27 We were unable to document any
relationship between CsA and the handling of urate during the long-term follow-up in our
patients, but a strong relationship was seen between hyperuricemia and GFR. The cause of
the hyperuricemia after renal TX is probably multifactorial and the above-mentioned
factors are not mutually exclusive. In the report by Laine et al., patients were investigated 6
months after TX and differed from the patients in this study, in both higher CsA doses and
better graft function.27
In most of our patients, urinary concentrating capacity was slightly reduced (Figure
4). This has previously been shown in pediatric kidney recipients but also after liver
transplantation in children receiving CsA.124,291 The mechanisms are not fully understood,
but it seems likely that CsA plays a role.123
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RENAL HISTOPATHOLOGY (II)
In contrast to most other reports, in which CR is the leading cause of long-term graft
loss,38,56 the majority of the grafts (6/11) lost by our patients failed to survive because of
post–TX nephrosis in patients with NPHS1.71
Most of the biopsies (52-69%) were regarded as normal according to the BC,135 and
the proportion with chronic allograft nephropathy did not increase substantially with time
(Table 9). In a study by Broyer et al., 53% of pediatric CAD recipients with a long-term
functioning graft had chronic transplant nephropathy grade I at 12-18 months after TX.155
The most frequent individual findings in our long-term biopsies were glomerular
mesangial expansion, tubular atrophy, interstitial fibrosis with moderate inflammation, and
intimal hyperplasia (Table 10). Similar findings have all been described previously in
connection with chronic allograft nephropathy in adults and children.124,139,145,146
In our patients, the incidence of interstitial inflammation with focal lymphocytes
diminished between 1.5 and 7 years after TX. This may have reflected a slight decrease in
immunoactivation, even though renal function was stable and FNAB were normal or had
normalized. Diffuse fibrosis, which is regarded as irreversible, increased with time. The
incidence of mild tubular epithelial atrophy seemed to decrease with time. This may reflect
an adaptation process in the kidney or merely the beginning of an irreversible process
leading to extinction of the tubuli, together with the development of fibrosis. The casts in
the biopsies were almost exclusively hyaline casts. The diagnostic value of casts in renal
biopsies is limited.133 In this context, it is likely that they are connected with tubular
atrophy. The incidence of arterial intimal proliferation tends to increase with time, arteries
being more affected than arterioles. The latter observation is more compatible with
immunoactivation than with CsA toxicity.142 Intimal thickening without hypertension is also
suggestive of CR.135 Hypertension was not a problem in our patients; 90% were without
antihypertensive treatment at 3 years, and none of the patients with protocol biopsies had
received treatment after 5 or 7 years. However, biopsies years after TX and with impaired
graft function unfortunately offer little chance to reveal the etiology of the morphologic
findings.142
The most prominent histopathologic changes, calculated as the CADI score, were
consistent with the report by Isoniemi et al., who studied the histopathologic findings in
adult long-term renal allografts.139 In that study, 2 years after TX, the mean CADI score
was 1.5 (scale 0-18) in adults with triple immunosuppression. In our patients, the median
CADI scores ranged from 2.5 to 4.0 (scale 0-36) (Table 8 and Figure 3). Most
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importantly, the CADI score also remained stable with time, suggesting that the inevitable
progression of chronic allograft nephropathy was very modest in our patients.
AR is one of the major risk factors for development of CR, both in adults and
among pediatric CsA-treated recipients.57,58,159-161 In our study, patients with one or more
rejection episodes, even though mostly slight and responsive to steroids, had higher CADI
at every subsequent follow-up compared with those who had no rejection episodes. ∆CADI
between 1.5 and 5 years was also greater in the group with one or more rejection episodes
than in the group without rejection episodes. Thus, it seems that the histopathologic
changes due to early AR episodes progress with time and that early immunologic activation
initiates a cascade of events leading to tissue destruction.144 In our patients, neither graft
matching, nor cold ischemia time (CAD recipients), nor donor age had any effect on
histopathology.
Signs of acute CsA toxicity were rarely seen. This is understandable in view of the
moderate CsA doses used. CsA doses or blood levels did not correlate with any histological
parameter. However, the impact of CsA is difficult to assess in this study because the
patients’ CsA doses were continually adjusted according to blood trough levels, functional
parameters of toxicity,26,27 and histology.
It is conceivable that these mild histological findings individually had a minor effect
on graft function. However, when combined in the CADI score, they show a negative
correlation with function. Furthermore, patients with more chronic changes according to the
BC, had inferior function. The CADI score has previously been shown to have a predictive
value for later deterioration of graft function.140 In our patients, despite low CADI scorings,
3 years after TX they still correlated inversely with later graft function, and, in patients with
a higher CADI score, graft function was worse at later follow-up.
The difference in histological findings between CAD and LRD recipients was small.
In the CAD recipients, CADI was significantly higher only at 3 and 5 years. The CAD
recipients also had significantly more AR. However, the difference in absolute GFR
between the groups was not significant. The absolute GFR also remained stable with time
in both donor groups.
Global glomerular sclerosis increased significantly with time. The mean PSG was
only 3% at 1.5 years, but increased to 36% at 5 years. The mean age of the donor kidneys
was close to 30 years. The normal incidence of sclerotic glomeruli up to 40 years of age in
native kidneys is close to 2%, and an incidence of sclerotic glomeruli greater than 10% in
this age group is considered to be disease-related rather than related to normal
senescence.292 Allografts from donors >40 years did not have significantly more sclerosis
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than allografts from <40 years of age (data not shown). The effect of donor age on sclerosis
is difficult to evaluate, however, since very few of the donors used were old.
The increasing glomerular sclerosis may have been secondary to the functional and
structural adaptation of the glomeruli after loss of functioning nephrons leading to
hyperfiltration.151,173,174 The on-going demand that the transplanted kidney should increase
its function in response to growth of the child may cause hyperfiltration. However, it has
also been shown that children maintain their functional reserve capacity years after TX and,
consequently, do not hyperfiltrate maximally.130 As discussed earlier, inadequate perfusion
of the kidney in the very young recipient probably leads to irreversible loss of functioning
nephrons in the ASK. Glomerular sclerosis increased markedly with time in all the patients
in our study, but especially in the youngest recipients. This could be explained by the
greater hyperfiltration in the remaining nephrons with the growth of the child, which is
more marked in the youngest recipients. It could also be explained by the finding that the
lower perfusion and subsequent irreversible loss of functioning nephrons is greatest in the
youngest recipients. Whatever the cause, this process is self-perpetuating, since further
glomerulosclerosis lead to additional loss of functioning nephrons. It could be speculated
that, in small children, recipient functional and structural adaptation after renal allograft TX
is even more important for long-term success than immunologic disparity.128
GROWTH (III)
One of the most important aspects of care after TX is concern about the child’s growth.
This issue is perhaps more rewarding to discuss in the context of small children and infants
receiving a kidney graft. Most of the single centers report catch-up growth in small children
after TX.44,54,199,200 According to the results of multicenter registry reports, catch-up growth
occurs primarily in recipients <6 years of age at TX.198 Consistently, catch-up growth after
TX was seen in 81% of those children who had never received any GH in our study.
CRF inevitably affects growth,178 and the event of TX is always preceded by CRF.
With enhanced nutrition in CRF and during dialysis treatment, catch-up growth has been
observed in small children even prior to TX.195-197 The overall growth retardation in children
at the time of TX also seems to have diminished during the last 10 years.8  This
development is probably due, at least in part, to the use of GH in CRF.3 The growth
retardation in our patients was not so severe as usually reported at the time of TX.3
Obviously, we were successful in avoiding severe growth impairment in the majority of our
patients before TX, even without the use of GH.
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When the children who did not need GH were analyzed according to age (<2 vs. 2-5 years
at TX), we noticed that catch-up growth was seen mainly in the older age group (Table 8).
The height deficit at the time of TX has been shown to correlate with the height increment
following TX.198 The younger patients <2 years old had clearly less growth impairment than
the patients 2-5 years of age at TX. In our study, the hSDS score at TX showed an inverse
correlation with the later height increment and ruled out age as a determinant of the later
height increment in a multiple regression model. Similarly, the hBA at TX, but not age,
also showed a very strong inverse correlation with the later increment in hBA.
In many of the previous studies, the height deficit at the time of TX was particularly
marked in the youngest recipients, ranging from -2.1 to -3.7.44,54,199,200 In the 1997
NAPRTCS report, the mean hSDS at TX was similar in children <2 years and 2-5 years,
-2.57 vs. -2.58, respectively. One can speculate, at least in the youngest age groups, that the
“physiological demand” of catch-up growth is a stronger determinant than the age of the
recipient for reaching the genetically determined target height.
Reduced allograft function impairs growth in CRF and after TX.203,211 In many
earlier reports, a deterioration of standardized growth was seen a few years after TX.
Although not reported in detail, it seemed to be related to deterioration of graft function
with time.54,293 In our study, GFR at 5 years predicted the subsequent growth rate. As
discussed earlier, the youngest recipients receiving an adult graft did not maintain their
long-term graft function in response to body growth. The body-size-related GFR decreased
more rapidly and earlier in recipients <2 years of age at TX. Thus, this is another possible
explanation for the lack of catch-up growth in this age group in our study. Impaired renal
function is probably one of the main factors affecting long-term growth.
Use of CS after TX inevitably affects growth.35 All our patients received steroids on
alternate days. Thus, in our patients, the effect of steroids on growth in our patients cannot
be evaluated. However, we can conclude that, in the majority of our patients, a low dose,
alternate-day steroid regimen did not preclude catch-up growth, which is consistent with
other reports in the literature.204,205
GH treatment has accelerated growth and improved adult height significantly in
CRF and after TX.214,215,223 In our children given GH, growth was, not surprisingly, more
impressive than without the use of GH and catch-up growth occurred in all the patients.
However, GH was given to our patients in a nonrandom fashion, based on clinical grounds
to those children with a shorter stature at the beginning of treatment. Thus, the two groups
(with and without GH) are not comparable. Catch-up growth occurred in the GH-treated
group with GS similar to that in the non-treatment group, without a higher incidence of late
AR. CADI was slightly higher in the GH treatment group, but not significantly so. A
Discussion
85
tendency to a lower long-term GFR was seen in our GH treatment group, which requires
further studies, including more patients and a longer follow-up. Deterioration of graft
function related to the use of GH after TX has been reported,231,236,237 but has not been
confirmed in controlled studies.215,233 There have been variable results for GH influence on
bone maturation in CRF and after TX.215,223 In this study, GH treatment did not significantly
increase BA maturation.
Final height was dependent on the height at TX in the reports by Hokken-Koelega
and Rodriguez-Soriano et al.211,212 In order to ensure a growth percentile within normal
limits at TX, the use of GH during CRF and/or dialysis seems rational.294
Our patients showed some excessive weight gain during the follow-up. This is a
common problem and probably mainly related to the use of steroids.40 In our patients, MP
was tapered with time, but this excessive weight gain was probably caused by CS.
NEURODEVELOPMENTAL OUTCOME (IV-V)
The first reports in the literature on children treated for CRF from birth were extremely
disappointing.240,241 The children suffered from encephalopathies, neurological
complications and developmental delay. A successful TX was shown to improve
psychomotor development in many infants,200,244,279,280 but major handicaps affecting
cognitive performance will, of course, persist even after a successful TX. Much of the
progress made in the neurodevelopmental outcome of small children with CRF is not solely
attributable to TX. Vigorous nutritional support, treatment of uremic complications,
dialysis treatment, etc., have all contributed to the more favorable outcome.255,270 The
nutritional state of our patients, in terms of the W/H index, was satisfactory at the time of
TX. The mean head circumference measurements (as a correlation for brain development in
infants and small children) were also close to those reported by Warady et al., who had a
favorable outcome in infants on peritoneal dialysis.270
In 3 (9%) of our patients, cerebral infarcts led to severe neurological sequelae, such
as hemiplegia. These complications were documented prior to TX before 1989, when
anticoagulation treatment was routinely initiated in NPHS1 patients during nephrosis. We
believe that this was of crucial importance in patients with congenital nephrosis, reducing
serious thromboembolic complications during the 1990´s.
In the present study, we found a substantial number of watershed/border-zone
ischemic lesions even in patients with normal school and motor performance (Table 11).
The patients were all in a stable clinical condition at the time of the MRI studies. Internal
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junctional infarcts, the most common findings in our patients, were seen in 18 of the 33
patients, including all those scored as grade 1. Cortical watershed infarcts were seen in
eight patients, but never in the absence of internal junctional lesions. The ischemic lesions
in our patients were typically hypoperfusion infarcts and the two border-zone areas acted as
a continuum with the internal junctional region, being the areas most easily injured by
hypoperfusion. This finding conflicts with the suggestion of Mounier-Vehier et al.251 that
the subtypes of border-zone infarcts could be caused by different mechanisms.
A significant majority of the patients with border-zone lesions had a history of
hemodynamic crises. This suggests that, in our patients, hemodynamic crises were an
important etiologic factor for the border-zone infarcts. Our patients with major handicaps
and inferior school performance also had significantly more hypertensive crises than the
other patients.
If we consider hemodynamic crises and hypertensive vasculopathy as the main
causes of the vascular lesions, it is evident that these episodes were far more common
before than after TX. The prevalence of clinical hypertension also declined rapidly after
TX. In the pre-TX CT studies, large infarcts and also grade 3 watershed lesions were
already visible, whereas only three of the milder lesions were seen. CT is known to be less
sensitive than MRI in showing small periventricular white matter lesions. Thus it is logical
to assume that the grade 1 and 2 lesions also originated in the pre-TX period.
Patients with congenital nephrosis have a severe coagulation abnormality during
nephrosis6 and the incidence of minor lesions is possible and is consistent with the large
vessel infarcts seen before the initiation of anticoagulation treatment. However, the patients
with diagnoses other than NPHS1 had findings similar to those in the rest of the group, with
one grade 2 and two grade 1 border-zone lesions. The state of relative hypercoagulability
during dialysis is a also possible contributory factor.256
Prematurity is known to be a risk factor for vascular injury to the brain, but the
groups with border-zone lesions did not differ with respect to gestational age. The children
in the group who received special education were born significantly earlier; however, mild
prematurity is not usually included as a risk factor in neurodevelopmental studies.287
Artificial ventilation was required by two of them and this may have had some influence on
their later performance. However, artificial ventilation and neonatal complications were
likewise seen in patients whose later performance was normal. As the number of patients in
this study is relatively small, a full interpretation of the relationships between the numerous
possible neonatal risk factors is impossible.
The reported patchy white matter hyperintensities or symmetrical basal ganglia
lesions in connection with uremic encephalopathy are very different from the lesions in our
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patients.295 CsA toxicity may lead to an encephalopathy that is identical to hypertensive
encephalopathy.272 However, no clinical incidence of CsA toxicity was reported in
connection with any of the documented hypertensive crises.
In our patients, the prevalence of brain atrophy after TX was only 15%, and was
mostly mild. In the pre-TX CT images, severe dilatation of the cerebrospinal fluid spaces
was seen in 3 patients, but the finding normalized after TX. Thus, it did not represent true
atrophy but a reversible contraction of brain tissue caused by disturbances of electrolyte and
fluid balance, hypoproteinemia, medication, etc.296 The high prevalence of atrophy reported
in earlier studies252-254 may also, at least partially, be explained by these factors.
Eight of our children (24%) had seizures after TX, a figure comparable with earlier
reports.260,261 In the report by Awan et al.,260 only 5% required anticonvulsive treatment,
which is substantially lower than our reported 15%. However, only 2 of the 109 patients in
the report by Awan et al. had convulsions secondary to intracerebral pathology.260 In our
report, the patients receiving treatment all had ischemic intracerebral lesions. Children with
seizures after renal TX usually have a good prognosis and a good long-term neurological
outcome. The most important etiological factor is usually hypertension.260,261 Our patients
who received special education had had significantly more seizures. The same patients also
had significantly more hypertensive crises. In our patients, however, the prevalence of
seizures after TX was mainly a consequence of epilepsy secondary to intracerebral
pathology.
The prevalence of SNHL in our patients was 20%. Two patients (7%) had hearing
impairment and used hearing aids. This is close to the figure of 9% reported by Mancini et
al. in children with CRF in childhood.263 All the children with SNHL had histories of
several septic infections for which they had received potentially ototoxic antibiotic
treatment before TX. However, the etiology of SNHL in our patients is merely speculative
and is probably the combined result of many factors.267
In the special education group, the age at TX did not differ significantly from that of
rest of the patients. The total time on dialysis was longer, but this was due to a higher
incidence of graft failure in the special education group (i.e. reinstitution of dialysis). The
duration of dialysis before the first graft did not differ among the groups.
Although infections are the leading cause of mortality, none of our patients was lost
solely because of infection. The majority of severe septic infections were seen in the CNF
patients during nephrosis, mainly due to loss of gamma globulin and complement factors.6
Severe septic infections were not more common in the patients with a poorer
neurodevelopmental outcome, and seem to have been of minor importance as a risk factor.
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In a report by Andreoli et al.,187 children who developed aluminum intoxication, mainly
osteomalacia, had a mean S-Al level of 13.75 ± 6.6 µmol/L. A control group with a mean
level of 1.0 ± 0.68 did not have any signs of aluminum intoxication.187 In a review by
Trompeter et al.,297 the children were divided according to S-Al levels of above (group I)
and below (group II) 100 ng/mL (approximately 3.7 µmol/L); neurological complications
were seen almost exclusively in group I.297 None of our patients had a mean value above
100 ng/mL. All our patients with a mean S-Al above 1.0 µmol/L (range from 1.02 to 2.42)
had a normal school performance.
Seven (21%) of our patients attended a special school, two solely because of a
severe hearing handicap. The official figure for the general population in Finland is 3.7%.298
Twenty-six (79%) of our patients attended a normal school, and 23% of them received
remedial teaching. The official figure for the general population, including the children
receiving at least part-time remedial teaching in a normal class, is 14%.298 These figures are
comparable with earlier reports.273-275
All the children receiving remedial teaching had normal motor performance and,
regarding IQ and neuropsychological tests, did not differ significantly from the patients
attending full-time regular classrooms (Table 12). Thus, with respect to their
neurodevelopmental outcome, this subpopulation is not of major concern to us.
The neurodevelopmental outcome in this difficult patient population is gratifying.
We have to bear in mind that, two decades ago, these patients inevitably died. The patients
in our study were not investigated for cognitive function before TX. Even after a successful
TX, major handicaps affecting cognitive performance persist. It is promising, however, that
the majority of these high-risk patients have normal or near normal cognitive performance
at school age. The complications seen in our patients mostly occurred during CRF and
dialysis. The small sample size and heterogeneity, particularly in the special education
group, somewhat limit the analysis with respect to risk factors prior to TX. However, it
seems to be of crucial importance to minimize any possible risk factors, such as
hypertension, malnutrition, etc, before TX. This report includes the first patients treated at
our center and progress has since been made in many treatment modalities. At our center,
the children most recently treated with peritoneal dialysis have considerably less
hypertension, pulmonary edema, and fewer seizures than these early patients.196 We expect
that the neurodevelopmental outcome after TX due to renal insufficiency from infancy will
continue to improve in the future.
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CONCLUSIONS
Both short- and long-term results have improved after TX in children. However, small
children and infants still have had inferior patient survival and GS compared with older
children. Our results are comparable with the best results achieved with LRD TX in infants
and children less than 5 years of age at TX. More importantly, they clearly indicate that the
disadvantage of CAD TX in small children can be overcome.
1. Our results indicate that, good long-term function and a low incidence of chronic
allograft nephropathy can be achieved with a strict protocol of follow-up, including
monitoring of CsA treatment. The majority of graft losses were, in fact, on account of
recurrence of nephrosis in children with NPHS1.
2. In children, maintenance of graft function is not enough. In order to cope with the
increasing demand of a growing child, graft function has to improve. The youngest children
<2 years of age at TX did not improve their GFR with time, which would have been a
prerequisite for maintaining the body size-related GFR. The CADI was similar and the
numbers of AR were equally distributed between the age groups <2 and between 2–5 years
of age. However, glomerular sclerosis increased with time, particularly in the youngest
recipients, which could be explained by the greater hyperfiltration in the allografts.
3. Catch-up growth after TX is usually reported in children <6 years of age. In this
study, the results are consistent with this and catch-up growth was seen in the majority of
patients. However, our results indicate that the height deficit at the time of TX is a stronger
indicator than age for catch-up growth in small children. GH treatment ensures remarkable
catch-up growth in some of the patients without a significant negative impact on long-term
allograft function or histopathology.
4. The positive impact of TX on development encourages early TX in children with
CRF. However, a favorable neurodevelopmental outcome is not solely dependent on the
outcome after TX. Major handicaps will persist even after a successful TX. Anticoagulation
therapy in hypoproteinemic diseases and aggressive therapy for hypertension and
hyper/hypovolemia during dialysis seem to be of major importance for avoiding
neurodevelopmental complications.
We have to consider that this study includes the first 50 children <5 years of age,
and the first children with NPHS1 treated at our institution. Two decades ago, these patients
inevitably died. Thus, the overall results are most rewarding.
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